Carlisle
Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	Obs O	Exp	SIR	ieu case counts, w <u>95% CI</u>	illi Standardized incidenc	Obs	Exp	SIR	95% CI
Bladder, Urina		<u>Γν</u> ρ	SIIX	<u>73 /6 CI</u>	Melanoma of Skin	003	LVh	SIIX	73 /0 CI
Male	4	4.5	nc	(nc-nc)	Male	3	2.8	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	Female	4	2.1	nc	(nc-nc)
Brain and Othe				(He He)	Multiple Myeloma	'	2.1	110	(no no)
Male	1	1.0	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Breast</u>		0.0	110	(no no)	Non-Hodgkin Lympl		0.1	110	(no no)
Male	0	0.2	nc	(nc-nc)	Male	2	2.6	nc	(nc-nc)
Female	30	19.0	158.2	(106.7-225.8)	Female	2	1.9	nc	(nc-nc)
Cervix Uteri				(10011 ==010)	Oral Cavity & Phary				(**************************************
					Male	_ 2	2.3	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
Colon / Rectum				,	Ovary				, ,
Male	3	7.2	nc	(nc-nc)					
Female	4	5.2	nc	(nc-nc)	Female	1	1.9	nc	(nc-nc)
Esophagus					<u>Pancreas</u>				
Male	0	1.3	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
Hodgkin Lymp	<u>homa</u>				<u>Prostate</u>				
Male	1	0.4	nc	(nc-nc)	Male	27	22.1	122.4	(80.6-178.1)
Female	1	0.3	nc	(nc-nc)					
Kidney & Rena	I Pelvis				<u>Stomach</u>				
Male	0	2.3	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	1.0	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	0	1.5	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	0	1.8	nc	(nc-nc)
Liver and Intra	hepatic	Bile Duc	<u>ts</u>		Uteri Corpus and Ut	erus, NOS	<u>S</u>		
Male	0	1.1	nc	(nc-nc)					
Female	0	0.3	nc	(nc-nc)	Female	1	3.9	nc	(nc-nc)
Lung and Bron	<u>ichus</u>				All Sites / Types				
Male	4	9.3	nc	(nc-nc)	Male	52	68.2	76.3	(57.0-100.1)
Female	3	6.9	nc	(nc-nc)	Female	53	55.3	95.9	(71.8-125.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Carver
Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

			•		vith Standardized Incider				050/ 01
	<u>Obs</u>	<u>Ехр</u>	<u>SIR</u>	<u>95% CI</u>	Malanana af Chin	<u>Obs</u>	<u>Exp</u>	SIR	<u>95% CI</u>
Bladder, Urinary		10.1	01.4	(47.0.450.7)	Melanoma of Skin	0		117.0	(50.7.000.0)
Male	12	13.1	91.4	(47.2-159.7)	Male	8	6.8	117.9	(50.7-232.2)
Female	6	4.3	138.8	(50.7-302.0)	Female	3	5.2	nc	(nc-nc)
Brain and Other		-	<u>m</u>		Multiple Myeloma				
Male	4	2.4	nc	(nc-nc)	Male	3	1.9	nc	(nc-nc)
Female	1	2.0	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<u>Breast</u>					Non-Hodgkin Lym	<u>ohoma</u>			
Male	0	0.4	nc	(nc-nc)	Male	6	6.6	91.1	(33.3-198.4)
Female	39	45.3	86.2	(61.3-117.8)	Female	3	5.7	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Phar	<u>ynx</u>			
					Male	7	4.7	148.8	(59.6-306.7)
Female	3	2.0	nc	(nc-nc)	Female	2	2.2	nc	(nc-nc)
Colon / Rectum					<u>Ovary</u>				
Male	21	19.8	106.3	(65.8-162.5)					
Female	21	17.8	118.3	(73.2-180.8)	Female	7	4.8	146.6	(58.7-302.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	3.2	190.3	(69.5-414.3)	Male	5	3.7	134.5	(43.3-313.9)
Female	1	0.9	nc	(nc-nc)	Female	6	3.8	159.1	(58.1-346.2)
Hodgkin Lympho	<u>oma</u>				<u>Prostate</u>				
Male	1	1.0	nc	(nc-nc)	Male	52	49.8	104.4	(78.0-137.0)
Female	0	0.8	nc	(nc-nc)					
Kidney & Renal F	<u>Pelvis</u>				<u>Stomach</u>				
Male	9	5.2	173.2	(79.0-328.8)	Male	5	3.3	149.6	(48.2-349.1)
Female	8	3.2	247.8	(106.7-488.4)	Female	4	1.8	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	1	2.2	nc	(nc-nc)	Male	3	1.6	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	8	4.1	197.1	(84.8-388.3)	Male	3	1.3	nc	(nc-nc)
Female	4	3.2	nc	(nc-nc)	Female	5	4.2	118.8	(38.3-277.2)
Liver and Intrahe	patic I	Bile Duct	<u>ts</u>		Uteri Corpus and L	Jterus, NO	<u> </u>		
Male	1	2.4	nc	(nc-nc)					
Female	1	0.9	nc	(nc-nc)	Female	7	9.0	77.4	(31.0-159.5)
Lung and Bronch	<u>nus</u>				All Sites / Types				
Male	23	24.5	94.0	(59.5-141.0)	Male	192	169.6	113.2	(97.8-130.4)
Female	24	21.0	114.2	(73.1-169.9)	Female	160	151.3	105.8	(90.0-123.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Charlemont
Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

95% CI <u>Obs</u> <u>Exp</u> SIR Obs Exp SIR 95% CI Bladder, Urinary Melanoma of Skin Male 1 1.4 nc (nc-nc) Male 0 8.0 nc (nc-nc) Female 1 0.5 nc (nc-nc) Female 0 0.6 nc (nc-nc) **Brain and Other Nervous System** Multiple Myeloma Male 0 0.3 Male 1 0.2 nc (nc-nc) nc (nc-nc) Female 0 0.2 (nc-nc) Female 0 0.1 nc nc (nc-nc) **Breast** Non-Hodgkin Lymphoma Male 0 0.0 nc (nc-nc) Male 0.7 nc (nc-nc) Female 8 5.3 150.5 (64.8-296.6)Female 0 0.6 (nc-nc) nc Cervix Uteri Oral Cavity & Pharynx Male 0 0.6 (nc-nc) nc 0 Female 0 0.2 Female 0.3 (nc-nc) nc (nc-nc) nc Colon / Rectum Ovary Male 1 2.1 (nc-nc) nc Female 3 1.9 nc (nc-nc) Female 0 0.6 nc (nc-nc) **Esophagus Pancreas** Male 0 0.4 nc (nc-nc) Male 1 0.4 nc (nc-nc) Female 0 0.1 nc (nc-nc) Female 1 0.4 nc (nc-nc) Hodgkin Lymphoma **Prostate** Male 0 0.1 Male 5 6.1 82.5 (26.6-192.6) (nc-nc) nc Female 0 0.1 (nc-nc) nc Kidney & Renal Pelvis Stomach Male 0 0.6 Male 0 0.3 (nc-nc) nc (nc-nc) nc Female 1 0.4 Female 0 0.2 nc (nc-nc) nc (nc-nc) <u>Testis</u> <u>Larynx</u> Male 0 0 0.2 0.3 nc (nc-nc) Male nc (nc-nc) Female 0 0.1 nc (nc-nc) <u>Leukemia</u> **Thyroid** 0 Male 1 0.4 nc (nc-nc) Male 0.2 nc (nc-nc) Female 0 0.3 Female 0 0.5 (nc-nc) nc (nc-nc) nc **Liver and Intrahepatic Bile Ducts** Uteri Corpus and Uterus, NOS Male 0 0.3 (nc-nc) nc Female 0 0.1 0 nc (nc-nc) Female 1.1 nc (nc-nc) Lung and Bronchus All Sites / Types Male 3 2.7 Male 14 19.3 72.4 (39.5-121.4) nc (nc-nc) Female 1 2.2 nc (nc-nc) Female 16 17.0 94.0 (53.7-152.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

CharltonObserved and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	Obs C	Exp	and Expec	95% CI	With Standardized inclus	Obs	25, 1999-20 <u>Exp</u>	رن SIR	<u>95% CI</u>
Bladder, Urina		LVA	<u> 5110</u>	<u>7370 CI</u>	Melanoma of Skin		LAP	JIIC	<u>7370 CI</u>
Male	 7	8.2	85.2	(34.1-175.6)	Male	1	5.3	nc	(nc-nc)
Female	3	2.8	nc	(nc-nc)	Female	1	4.4	nc	(nc-nc)
Brain and Othe	r Nervo		m	, ,	Multiple Myeloma				, ,
Male	6	2.0	297.3	(108.6-647.1)	Male	1	1.3	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Breast</u>					Non-Hodgkin Lym	phoma			
Male	0	0.3	nc	(nc-nc)	Male	3	4.9	nc	(nc-nc)
Female	37	35.2	105.0	(73.9-144.8)	Female	6	4.0	151.5	(55.3-329.7)
Cervix Uteri					Oral Cavity & Pha	<u>rynx</u>			
					Male	3	3.7	nc	(nc-nc)
Female	2	1.9	nc	(nc-nc)	Female	2	1.7	nc	(nc-nc)
Colon / Rectum	<u>1</u>				<u>Ovary</u>				
Male	13	12.9	100.7	(53.6-172.2)					
Female	16	11.6	137.4	(78.5-223.2)	Female	3	3.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	2.2	nc	(nc-nc)	Male	2	2.4	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	3	2.4	nc	(nc-nc)
Hodgkin Lymp	<u>homa</u>				<u>Prostate</u>				
Male	1	0.9	nc	(nc-nc)	Male	39	34.5	113.0	(80.4-154.5)
Female	0	8.0	nc	(nc-nc)					
Kidney & Rena	<u>I Pelvis</u>				<u>Stomach</u>				
Male	5	3.9	128.9	(41.5-300.7)	Male	2	2.2	nc	(nc-nc)
Female	4	2.2	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	1	1.6	nc	(nc-nc)	Male	3	1.8	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	3	2.9	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	3	2.4	nc	(nc-nc)	Female	2	4.2	nc	(nc-nc)
Liver and Intra	•				Uteri Corpus and	Uterus, N	<u>IOS</u>		
Male .	2	1.8	nc	(nc-nc)			1		
Female	0	0.6	nc	(nc-nc)	Female	15	6.7	222.6	(124.5-367.2)
Lung and Bron		45.0	460.0	(70.0.107.1)	All Sites / Types	465	4	100 =	(OF 0 100 F)
Male	19	15.8	120.0	(72.2-187.4)	Male	122		103.5	(85.9-123.5)
Female	13	13.2	98.8	(52.6-169.0)	Female	124	110.3	112.4	(93.5-134.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Chatham
Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

			•		with Standardized Incide					
	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Ехр</u>	<u>SIR</u>	<u>95% CI</u>	
Bladder, Urina	<u>ry</u>				Melanoma of Skin					
Male	23	16.7	137.8	(87.4-206.8)	Male	14	7.1	197.8	(108.1-332.0)	
Female	9	5.7	157.9	(72.1-299.8)	Female	10	4.9	204.2	(97.7-375.5)	
Brain and Othe	r Nervo	us Syste	<u>em</u>		Multiple Myeloma					
Male	5	2.1	234.0	(75.4-546.1)	Male	1	2.3	nc	(nc-nc)	
Female	0	1.9	nc	(nc-nc)	Female	0	1.8	nc	(nc-nc)	
<u>Breast</u>					Non-Hodgkin Lym	<u>ohoma</u>				
Male	2	0.5	nc	(nc-nc)	Male	6	7.2	83.9	(30.6-182.5)	
Female	79	47.1	167.7	(132.8-209.0)	Female	8	6.7	118.6	(51.1-233.8)	
Cervix Uteri					Oral Cavity & Phar	<u>ynx</u>				
					Male	7	4.8	144.4	(57.8-297.5)	
Female	2	1.6	nc	(nc-nc)	Female	3	2.6	nc	(nc-nc)	
Colon / Rectun	<u>1</u>				<u>Ovary</u>					
Male	20	24.2	82.6	(50.4-127.5)						
Female	25	23.8	105.0	(67.9-155.0)	Female	9	5.2	174.2	(79.5-330.8)	
Esophagus					<u>Pancreas</u>					
Male	7	3.7	187.6	(75.2-386.6)	Male	7	4.5	153.9	(61.7-317.1)	
Female	1	1.1	nc	(nc-nc)	Female	6	5.1	117.9	(43.1-256.6)	
Hodgkin Lymp	<u>homa</u>				<u>Prostate</u>					
Male	0	0.7	nc	(nc-nc)	Male	77	60.7	126.8	(100.0-158.5)	
Female	1	0.5	nc	(nc-nc)						
Kidney & Rena	I Pelvis				Stomach .					
Male	12	5.7	210.4	(108.6-367.6)	Male	2	4.1	nc	(nc-nc)	
Female	3	3.7	nc	(nc-nc)	Female	1	2.6	nc	(nc-nc)	
<u>Larynx</u>					<u>Testis</u>					
Male	4	2.5	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)	
Female	0	0.7	nc	(nc-nc)						
<u>Leukemia</u>					<u>Thyroid</u>					
Male	3	4.4	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)	
Female	3	3.7	nc	(nc-nc)	Female	3	2.8	nc	(nc-nc)	
Liver and Intra	hepatic I	Bile Duc	ts.		Uteri Corpus and L	Jterus, N	<u>IOS</u>			
Male	1	2.6	nc	(nc-nc)						
Female	0	1.1	nc	(nc-nc)	Female	13	9.8	132.2	(70.3-226.1)	
Lung and Bron	Lung and Bronchus				All Sites / Types					
Male	18	30.2	59.5	(35.3-94.1)	Male	225	199.7	112.6	(98.4-128.4)	
Female	17	25.9	65.7	(38.3-105.2)	Female	212	172.4	122.9	(107.0-140.7)	

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Chelmsford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

			•		with Standardized Incide				250/ 21
DI 11 11.	<u>Obs</u>	<u>Ехр</u>	<u>SIR</u>	<u>95% CI</u>	M I (CI)	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
Bladder, Urina				(10.1.00.0)	Melanoma of Skin				(=0.0.4=4.0)
Male	23	34.6	66.5	(42.1-99.8)	Male	19	19.6	96.9	(58.3-151.3)
Female	18	13.3	135.0	(79.9-213.3)	Female	10	16.8	59.7	(28.6-109.7)
Brain and Oth	er Nervo	-	_ '		<u>Multiple Myeloma</u>				
Male	6	7.0	85.4	(31.2-185.9)	Male	4	5.1	nc	(nc-nc)
Female	2	6.3	nc	(nc-nc)	Female	2	4.3	nc	(nc-nc)
<u>Breast</u>					Non-Hodgkin Lym	<u>phoma</u>			
Male	1	1.1	nc	(nc-nc)	Male	22	18.4	119.4	(74.8-180.8)
Female	148	146.3	101.2	(85.5-118.9)	Female	22	17.5	125.5	(78.6-189.9)
Cervix Uteri					Oral Cavity & Phar	<u>ynx</u>			
					Male	11	14.3	77.0	(38.4-137.8)
Female	4	6.5	nc	(nc-nc)	Female	6	7.2	83.7	(30.6-182.3)
Colon / Rectur	<u>m</u>				<u>Ovary</u>				
Male	56	53.2	105.3	(79.6-136.8)					
Female	55	54.2	101.5	(76.4-132.1)	Female	12	15.3	78.6	(40.6-137.3)
Esophagus					<u>Pancreas</u>				
Male	8	9.1	88.4	(38.0-174.1)	Male	10	10.1	98.9	(47.4-181.9)
Female	3	2.6	nc	(nc-nc)	Female	10	11.4	87.6	(41.9-161.0)
Hodgkin Lymp	<u>ohoma</u>				<u>Prostate</u>				
Male	2	2.9	nc	(nc-nc)	Male	167	150.2	111.2	(95.0-129.4)
Female	4	2.5	nc	(nc-nc)					
Kidney & Rena	al Pelvis				<u>Stomach</u>				
Male	19	15.3	124.1	(74.7-193.8)	Male	4	8.9	nc	(nc-nc)
Female	10	10.1	99.4	(47.6-182.8)	Female	3	5.6	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	5	6.4	77.7	(25.1-181.4)	Male	5	5.3	94.7	(30.5-221.0)
Female	1	1.9	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	12	11.1	107.7	(55.6-188.2)	Male	8	4.1	194.1	(83.6-382.5)
Female	10	9.7	103.0	(49.3-189.4)	Female	20	13.6	147.2	(89.9-227.4)
Liver and Intra	hepatic	Bile Ducts	<u>S</u>		Uteri Corpus and I	Jterus, NO	<u>)S</u>		
Male	12	7.1	168.6	(87.0-294.5)					
Female	2	2.7	nc	(nc-nc)	Female	30	30.1	99.7	(67.3-142.4)
Lung and Bro	nchus				All Sites / Types				
Male	67	67.8	98.8	(76.6-125.5)	Male	492	483.0	101.9	(93.1-111.3)
Female	55	64.7	85.0	(64.0-110.6)	Female	455	476.9	95.4	(86.8-104.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Chelsea
Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

Obs		•	·	with Standardized Incide				050/ 01
Obs	<u> Exp</u>	<u>SIR</u>	<u>95% CI</u>	Malanana of Chia	<u>Obs</u>	<u>Exp</u>	SIR	<u>95% CI</u>
Bladder, Urinary	21.0	100 7	(75.0.450.0)	Melanoma of Skin	-	1/0	00.7	(0 F (0 1)
Male 34		109.7	(75.9-153.3)	Male	5	16.9	29.6	(9.5-69.1)
Female 11		104.1	(51.9-186.3)	Female	12	13.5	88.6	(45.7-154.7)
Brain and Other Ne	_			<u>Multiple Myeloma</u>				
Male		110.2	(44.1-227.0)	Male	10		224.2	(107.3-412.4)
Female 9	5.3	169.9	(77.5-322.5)	Female	0	3.4	nc	(nc-nc)
<u>Breast</u>				Non-Hodgkin Lym	<u>phoma</u>			
Male (1.0	nc	(nc-nc)	Male	19	16.3	116.2	(70.0-181.5)
Female 82	106.6	76.9	(61.2-95.4)	Female	17	14.0	121.2	(70.5-194.0)
Cervix Uteri				Oral Cavity & Pha	<u>rynx</u>			
				Male	18	11.2	160.9	(95.3-254.4)
Female 14	5.2	269.6	(147.3-452.4)	Female	0	5.5	nc	(nc-nc)
Colon / Rectum				<u>Ovary</u>				
Male 45	46.6	96.5	(70.4-129.1)					
Female 48	3 44.1	108.8	(80.2-144.3)	Female	12	11.5	104.0	(53.7-181.7)
Esophagus				<u>Pancreas</u>				
Male 17	7.5	227.8	(132.6-364.7)	Male	12	8.7	137.2	(70.8-239.7)
Female 2	2.1	nc	(nc-nc)	Female	7	9.3	75.6	(30.3-155.8)
Hodgkin Lymphom	<u>a</u>			<u>Prostate</u>				
Male 3	3.1	nc	(nc-nc)	Male	85	119.1	71.4	(57.0-88.3)
Female 1	2.6	nc	(nc-nc)					
Kidney & Renal Pel	<u>vis</u>			<u>Stomach</u>				
Male 19	12.4	152.7	(91.9-238.6)	Male	10	8.0	125.4	(60.1-230.7)
Female 10	7.7	130.2	(62.3-239.5)	Female	5	4.8	104.6	(33.7-244.0)
<u>Larynx</u>				<u>Testis</u>				
Male 15	5.2	291.2	(162.8-480.3)	Male	2	6.1	nc	(nc-nc)
Female 3	1.3	nc	(nc-nc)					
<u>Leukemia</u>				<u>Thyroid</u>				
Male 8	10.3	77.7	(33.5-153.1)	Male	4	3.6	nc	(nc-nc)
Female 8	8.3	95.9	(41.3-189.0)	Female	10	11.6	86.1	(41.2-158.3)
Liver and Intrahepa	tic Bile Duc	ets.		Uteri Corpus and	Uterus, I	NOS		
Male 10	5.7	174.2	(83.4-320.4)					
Female 3	3 2.2	nc	(nc-nc)	Female	25	21.2	117.8	(76.2-173.8)
Lung and Bronchus	<u> </u>			All Sites / Types				
Male 66	57.6	114.6	(88.6-145.8)	Male	422	409.8	103.0	(93.4-113.3)
Female 51	49.0	104.2	(77.6-137.0)	Female	363	368.3	98.6	(88.7-109.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Cheshire
Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

Obs Exp SIR 95% CI Bladder, Urinary Melanoma of Skin Male 3 4.4 nc (nc-nc) Male 1 2.4 nc (nc-nc) Female 0 1.3 nc (nc-nc) Female 3 1.6 nc (nc-nc) Brain and Other Nervows System Multiple Myeloma Male 4 0.8 nc (nc-nc) Male 0 0.6 nc (nc-nc) Female 2 0.6 nc (nc-nc) Female 2 0.4 nc (nc-nc) Breast Non-Hodgkin Lymphoma Male 0 0.1 nc (nc-nc) Male 4 2.3 nc (nc-nc) Female 13 14.4 90.6 (48.2-154.9) Female 1 1.7 nc (nc-nc) Cervix Uteri Male 2 1.7 nc (nc-nc)
Male 3 4.4 nc (nc-nc) Male 1 2.4 nc (nc-nc) Female 0 1.3 nc (nc-nc) Female 3 1.6 nc (nc-nc) Brain and Other Verveus System Multiple Myeloma Male 4 0.8 nc (nc-nc) Male 0 0.6 nc (nc-nc) Female 2 0.6 nc (nc-nc) Female 2 0.4 nc (nc-nc) Breast Non-Hodgkin Lymphoma Male 0 0.1 nc (nc-nc) Male 4 2.3 nc (nc-nc) Female 13 14.4 90.6 (48.2-154.9) Female 1 1.7 nc (nc-nc) Cervix Uteri Male 2 1.7 nc (nc-nc) Female 0 0.6 nc (nc-nc) Female 0 0.7 nc (nc-nc)
Female 0 1.3 nc (nc-nc) Female 3 1.6 nc (nc-nc) Brain and Other Nervous System Multiple Myeloma Male 4 0.8 nc (nc-nc) Male 0 0.6 nc (nc-nc) Female 2 0.6 nc (nc-nc) Female 2 0.4 nc (nc-nc) Breast Mon-Hodgkin Lymphoma Male 0 0.1 nc (nc-nc) Male 4 2.3 nc (nc-nc) Female 13 14.4 90.6 (48.2-154.9) Female 1 1.7 nc (nc-nc) Cervix Uteri Male 2 1.7 nc (nc-nc) Female 0 0.6 nc (nc-nc) Female 2 1.7 nc (nc-nc) Colon / Rectum 0 0.8 88.8 (32.4-193.3) Female 0 1.5 nc (nc-nc) Male
Brain and Other Nervous System Multiple Myeloma Male 4 0.8 nc (nc-nc) Male 0 0.6 nc (nc-nc) Female 2 0.6 nc (nc-nc) Breast Non-Hodgkin Lymphoma Male 0 0.1 nc (nc-nc) Male 4 2.3 nc (nc-nc) Female 13 14.4 90.6 (48.2-154.9) Female 1 1.7 nc (nc-nc) Cervix Uteri Male 2 1.7 nc (nc-nc) Female 0 0.6 nc (nc-nc) Female 2 1.7 nc (nc-nc) Female 0 0.6 nc (nc-nc) Female 0 0.7 nc (nc-nc) Colon / Rectum Male 6 6.8 88.8 (32.4-193.3) Female 0 1.5 nc (nc-nc) Female 5 5.1 </td
Male 4 0.8 nc (nc-nc) Male 0 0.6 nc (nc-nc) Female 2 0.6 nc (nc-nc) Female 2 0.4 nc (nc-nc) Breast Non-Hodgkin Lymphoma Male 0 0.1 nc (nc-nc) Male 4 2.3 nc (nc-nc) Female 13 14.4 90.6 (48.2-154.9) Female 1 1.7 nc (nc-nc) Cervix Uteri Male 2 1.7 nc (nc-nc) Female 0 0.6 nc (nc-nc) Female 0 0.7 nc (nc-nc) Colon / Rectum Ovary Male 6 6.8 88.8 (32.4-193.3) (nc-nc) Female 0 1.5 nc (nc-nc) Female 5 5.1 97.5 (31.4-227.6) Female 0 1.5 nc (nc-nc)
Female 2 0.6 nc (nc-nc) Female 2 0.4 nc (nc-nc) Breast Non-Hodgkin Lymphoma Male 0 0.1 nc (nc-nc) Male 4 2.3 nc (nc-nc) Female 13 14.4 90.6 (48.2-154.9) Female 1 1.7 nc (nc-nc) Cervix Uteri Male 2 1.7 nc (nc-nc) Female 0 0.6 nc (nc-nc) Female 0 0.7 nc (nc-nc) Colon / Rectum Ovary Demale 0 1.5 nc (nc-nc) Female 5 5.1 97.5 (31.4-227.6) Female 0 1.5 nc (nc-nc)
Mon-Hodgkin Lymphoma Male 0 0.1 nc (nc-nc) Male 4 2.3 nc (nc-nc) Female 13 14.4 90.6 (48.2-154.9) Female 1 1.7 nc (nc-nc) Cervix Uteri Male 2 1.7 nc (nc-nc) Female 0 0.6 nc (nc-nc) Female 0 0.7 nc (nc-nc) Colon / Rectum Ovary Male 6 6.8 88.8 (32.4-193.3) Female 0 1.5 nc (nc-nc) Female 5 5.1 97.5 (31.4-227.6) Female 0 1.5 nc (nc-nc)
Male 0 0.1 nc (nc-nc) Male 4 2.3 nc (nc-nc) Female 13 14.4 90.6 (48.2-154.9) Female 1 1.7 nc (nc-nc) Cervix Uteri Male 2 1.7 nc (nc-nc) Female 0 0.6 nc (nc-nc) Female 0 0.7 nc (nc-nc) Colon / Rectum Ovary Male 6 6.8 88.8 (32.4-193.3) Female 0 1.5 nc (nc-nc) Female 5 5.1 97.5 (31.4-227.6) Female 0 1.5 nc (nc-nc)
Female 13 14.4 90.6 (48.2-154.9) Female 1 1.7 nc (nc-nc) Cervix Uteri Oral Cavity & Pharynx Male 2 1.7 nc (nc-nc) Female 0 0.6 nc (nc-nc) Female 0 0.7 nc (nc-nc) Colon / Rectum Male 6 6.8 88.8 (32.4-193.3) Female 0 1.5 nc (nc-nc) Female 5 5.1 97.5 (31.4-227.6) Female 0 1.5 nc (nc-nc)
Cervix Uteri Oral Cavity & Pharynx Female 0 0.6 nc (nc-nc) Female 0 0.7 nc (nc-nc) Colon / Rectum Ovary Ovary V V V V V Male 6 6.8 88.8 (32.4-193.3) V Female 0 1.5 nc (nc-nc) Female 5 5.1 97.5 (31.4-227.6) Female 0 1.5 nc (nc-nc)
Female 0 0.6 nc (nc-nc) Female 0 0.7 nc (nc-nc) Colon / Rectum Ovary V<
Female 0 0.6 nc (nc-nc) Female 0 0.7 nc (nc-nc) Colon / Rectum Ovary Male 6 6.8 88.8 (32.4-193.3) Female 0 1.5 nc (nc-nc) Female 5 5.1 97.5 (31.4-227.6) Female 0 1.5 nc (nc-nc)
Colon / Rectum Ovary Male 6 6.8 88.8 (32.4-193.3) Female 5 5.1 97.5 (31.4-227.6) Female 0 1.5 nc (nc-nc)
Male 6 6.8 88.8 (32.4-193.3) Female 5 5.1 97.5 (31.4-227.6) Female 0 1.5 nc (nc-nc)
Female 5 5.1 97.5 (31.4-227.6) Female 0 1.5 nc (nc-nc)
Esophagus Pancreas
Male 3 1.1 nc (nc-nc) Male 0 1.3 nc (nc-nc)
Female 0 0.3 nc (nc-nc) Female 4 1.1 nc (nc-nc)
Hodgkin Lymphoma Prostate
Male 1 0.3 nc (nc-nc) Male 16 18.5 86.5 (49.4-140.6)
Female 0 0.2 nc (nc-nc)
Kidney & Renal Pelvis Stomach
Male 1 1.9 nc (nc-nc) Male 1 1.1 nc (nc-nc)
Female 2 1.0 nc (nc-nc) Female 0 0.5 nc (nc-nc)
<u>Larynx</u> <u>Testis</u>
Male 0 0.8 nc (nc-nc) Male 0 0.5 nc (nc-nc)
Female 1 0.2 nc (nc-nc)
<u>Leukemia</u> <u>Thyroid</u>
Male 3 1.4 nc (nc-nc) Male 0 0.5 nc (nc-nc)
Female 0 0.9 nc (nc-nc) Female 0 1.3 nc (nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u> <u>Uteri Corpus and Uterus, NOS</u>
Male 1 0.9 nc (nc-nc)
Female 0 0.3 nc (nc-nc) Female 2 2.9 nc (nc-nc)
Lung and Bronchus All Sites / Types
Male 10 8.5 117.4 (56.2-215.9) Male 56 59.8 93.7 (70.8-121.7)
Female 11 6.3 174.9 (87.2-313.0) Female 49 46.2 106.0 (78.4-140.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Chester
Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

Bladder, Urinary Exp SIR 95% CI Male 2 1.4 nc (nc-nc) Male 0 0.8 nc (nc-nc) Female 2 1.4 nc (nc-nc) Female 1 0.6 nc (nc-nc) Brain and Other Nerveus System Multiple Myeloma Male 1 0.3 nc (nc-nc) Female 0 0.2 nc (nc-nc) Female 0 0.2 nc (nc-nc) Female 0 0.1 nc (nc-nc) Breast Non-Hodgkin Lymphoms Male 0 0.0 nc (nc-nc) Female 1 0.8 nc (nc-nc) Female 7 5.0 139.7 (56.0-287.9) Female 1 0.6 nc (nc-nc) Cervix Uteri Male 1 0.6 nc (nc-nc) Female 0 0.2
Male 2 1.4 nc (nc-nc) Male 0 0.8 nc (nc-nc) Female 2 0.4 nc (nc-nc) Female 1 0.6 nc (nc-nc) Brain and Other Nervous System Multiple Myeloma Male 1 0.3 nc (nc-nc) Male 0 0.2 nc (nc-nc) Female 0 0.2 nc (nc-nc) Female 0 0.1 nc (nc-nc) Breast Non-Hodgkin Lymphoms Male 0 0.0 nc (nc-nc) Female 1 0.8 nc (nc-nc) Female 1 0.6 nc (nc-nc) Cervix Uteri
Female 2 0.4 nc (nc-nc) Female 1 0.6 nc (nc-nc) Brain and Other Nerveus System Multiple Myeloma Male 1 0.3 nc (nc-nc) Male 0 0.2 nc (nc-nc) Female 0 0.2 nc (nc-nc) Female 0 0.1 nc (nc-nc) Breast Non-Hodgkin Lymphoma Male 0 0.0 nc (nc-nc) Male 1 0.8 nc (nc-nc) Female 7 5.0 139.7 (56.0-287.9) Female 1 0.6 nc (nc-nc) Cervix Uteri Male 1 0.6 nc (nc-nc) Female 0 0.2 nc (nc-nc) Female 1 0.6 nc (nc-nc) Cervix Uteri Ne Ne Ne Ne Ne Ne Ne Ne Ne Ne </td
Brain and Other Nerveus System Multiple Myeloma Male 1 0.3 nc (nc-nc) Male 0 0.2 nc (nc-nc) Female 0 0.2 nc (nc-nc) Breast Mon-Hodgkin Lymphoma Male 0 0.0 nc (nc-nc) Male 1 0.8 nc (nc-nc) Female 7 5.0 139.7 (56.0-287.9) Female 1 0.6 nc (nc-nc) Cervix Uteri Male 1 0.6 nc (nc-nc) Female 0 0.2 nc (nc-nc) Female 1 0.6 nc (nc-nc) Female 1 0.6 nc (nc-nc) Female 0 0.2 nc (nc-nc) Female 1 0.6 nc (nc-nc) Colon / Rectum 0 0.2 nc (nc-nc)
Male 1 0.3 nc (nc-nc) Male 0 0.2 nc (nc-nc) Female 0 0.2 nc (nc-nc) Breast Non-Hodgkin Lymphoma Male 0 0.0 nc (nc-nc) Male 1 0.8 nc (nc-nc) Female 7 5.0 139.7 (56.0-287.9) Female 1 0.6 nc (nc-nc) Cervix Uteri Male 1 0.6 nc (nc-nc) Female 0 0.2 nc (nc-nc) Female 1 0.6 nc (nc-nc) Colon / Rectum 0 0.2 nc (nc-nc)
Female 0 0.2 nc (nc-nc) Female 0 0.1 nc (nc-nc) Breast Non-Hodgkin Lymphoma Male 0 0.0 nc (nc-nc) Male 1 0.8 nc (nc-nc) Female 7 5.0 139.7 (56.0-287.9) Female 1 0.6 nc (nc-nc) Cervix Uteri Male 1 0.6 nc (nc-nc) Female 0 0.2 nc (nc-nc) Female 1 0.6 nc (nc-nc) Female 1 0.6 nc (nc-nc) Female 1 0.6 nc (nc-nc) Female 1 0.6 nc (nc-nc) Ovary Ovary
Mon-Hodgkin Lymphoma Male 0 0.0 nc (nc-nc) Male 1 0.8 nc (nc-nc) Female 7 5.0 139.7 (56.0-287.9) Female 1 0.6 nc (nc-nc) Cervix Uteri Dral Cavity & Pharynx Male 1 0.6 nc (nc-nc) Female 0 0.2 nc (nc-nc) Female 1 0.6 nc (nc-nc) Colon / Rectum 0 0.2 nc (nc-nc)
Male 0 0.0 nc (nc-nc) Male 1 0.8 nc (nc-nc) Female 7 5.0 139.7 (56.0-287.9) Female 1 0.6 nc (nc-nc) Cervix Uteri Oral Cavity & Pharynx Male 1 0.6 nc (nc-nc) Female 0 0.2 nc (nc-nc) Female 1 0.2 nc (nc-nc) Colon / Rectum Ovary
Female 7 5.0 139.7 (56.0-287.9) Female 1 0.6 nc (nc-nc) Cervix Uteri Oral Cavity & Pharynx Male 1 0.6 nc (nc-nc) Female 0 0.2 nc (nc-nc) Female 1 0.2 nc (nc-nc) Colon / Rectum Colon / Rectum Ovary
Cervix Uteri Oral Cavity & Pharynx Male 1 0.6 nc (nc-nc) Female 0 0.2 nc (nc-nc) Female 1 0.2 nc (nc-nc) Colon / Rectum Ovary Ovary Colon / Rectum Ovary Colon / Rectum Colon / Rectum Ovary
Female 0 0.2 nc (nc-nc) Female 1 0.6 nc (nc-nc) Colon / Rectum Ovary Ovary Image: Colon / Rectum / R
Female 0 0.2 nc (nc-nc) Female 1 0.2 nc (nc-nc) Colon / Rectum Ovary
<u>Colon / Rectum</u> <u>Ovary</u>
Male 2 2.2 nc (nc-nc)
Female 1 1.7 nc (nc-nc) Female 2 0.5 nc (nc-nc)
<u>Esophagus</u> <u>Pancreas</u>
Male 0 0.4 nc (nc-nc) Male 0 0.4 nc (nc-nc)
Female 0 0.1 nc (nc-nc) Female 0 0.4 nc (nc-nc)
Hodgkin Lymphoma Prostate
Male 0 0.1 nc (nc-nc) Male 8 5.9 135.6 (58.4-267.2)
Female 0 0.1 nc (nc-nc)
Kidney & Renal Pelvis Stomach
Male 0 0.6 nc (nc-nc) Male 0 0.4 nc (nc-nc)
Female 0 0.3 nc (nc-nc) Female 0 0.2 nc (nc-nc)
<u>Larynx</u> <u>Testis</u>
Male 0 0.3 nc (nc-nc) Male 1 0.2 nc (nc-nc)
Female 0 0.1 nc (nc-nc)
<u>Leukemia</u> <u>Thyroid</u>
Male 2 0.5 nc (nc-nc) Male 0 0.2 nc (nc-nc)
Female 0 0.3 nc (nc-nc) Female 1 0.5 nc (nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u> <u>Uteri Corpus and Uterus, NOS</u>
Male 0 0.3 nc (nc-nc)
Female 0 0.1 nc (nc-nc) Female 1 1.0 nc (nc-nc)
<u>Lung and Bronchus</u> All Sites / Types
Male 3 2.7 nc (nc-nc) Male 22 19.4 113.3 (71.0-171.6)
Female 1 2.1 nc (nc-nc) Female 19 15.9 119.4 (71.8-186.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Chesterfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003 95% CI <u>Obs</u> <u>Exp</u> SIR Obs <u>Exp</u> SIR 95% CI Bladder, Urinary Melanoma of Skin Male 1 1.2 (nc-nc) Male 0 0.7 nc (nc-nc) nc Female 0 0.3 nc (nc-nc) Female 1 0.5 nc (nc-nc) Brain and Other Nervous System Multiple Myeloma Male 0 Male 1 0.2 0.2 nc (nc-nc) nc (nc-nc) 1 0 0.2 (nc-nc) Female 0.1 Female nc nc (nc-nc) Non-Hodgkin Lymphoma **Breast** 0.0 Male 0 (nc-nc) Male 0.6 nc (nc-nc) nc Female 4 4.4 (nc-nc) Female 0 0.5 (nc-nc) nc nc Cervix Uteri Oral Cavity & Pharynx Male 1 0.5 (nc-nc) nc 0 Female 0 0.2 Female 0.2 (nc-nc) nc (nc-nc) nc Colon / Rectum Ovary Male 0 1.8 (nc-nc) nc Female 1 1.4 nc (nc-nc) Female 1 0.5 nc (nc-nc) **Esophagus Pancreas** 0 Male 0 0.3 nc (nc-nc) Male 0.3 nc (nc-nc) Female 0 0.1 nc (nc-nc) Female 0 0.3 nc (nc-nc) Hodgkin Lymphoma **Prostate** Male 0 0.1 Male 3 5.0 (nc-nc) nc (nc-nc) nc Female 0 0.1 (nc-nc) nc Kidney & Renal Pelvis Stomach Male 0 0.5 Male 0 0.3 (nc-nc) nc (nc-nc) nc (nc-nc) Female 0.3 Female 0 0.1 0 nc (nc-nc) nc <u>Larynx</u> **Testis** 0 0.2 0 0.2 Male nc (nc-nc) Male nc (nc-nc) Female 0 0.1 nc (nc-nc) <u>Leukemia</u> **Thyroid** 0 Male 0 0.4 (nc-nc) Male 0.1 nc (nc-nc) nc Female 0 0.3 Female 0 0.5 (nc-nc) (nc-nc) nc nc Liver and Intrahepatic Bile Ducts Uteri Corpus and Uterus, NOS Male 0 0.3 (nc-nc) nc 0.9 Female 0.1 1 0 nc (nc-nc) Female nc (nc-nc) Lung and Bronchus All Sites / Types (20.9-95.5)Male 1 2.3 Male 8 16.5 48.5 (nc-nc)

Obs = observed case count; Exp = expected case count;

1.7

3

Female

- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

(nc-nc)

Shading indicates the statistical significance of the SIR at 95% level of probability;

nc

nc

nc = The SIR and 95% CI were not calculated when Obs < 5;

12

Female

13.5 89.2

(46.0-155.7)

Chicopee

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003 <u>Obs</u> **Exp** SIR 95% CI Obs SIR 95% CI <u>Exp</u> Bladder, Urinary Melanoma of Skin Male 69 68.8 100.3 (78.1-127.0) Male 30 34.5 86.9 (58.6-124.0)Female 28 26.5 105.8 (70.3-152.9) Female 21 28.6 73.4 (45.4-112.2)**Brain and Other Nervous System** Multiple Myeloma 11.9 Male 9.8 102.2 Male 14 118.1 (64.5-198.2) 10 (48.9-188.0)138.5 Female 13 11.1 116.7 (62.1-199.6)Female 12 8.7 (71.5-242.0)Non-Hodgkin Lymphoma **Breast** Male 0 2.1 nc (nc-nc) Male 31 33.7 92.0 (62.5-130.6)Female 250 251.6 99.3 (87.4-112.5) Female 24 33.6 71.5 (45.8-106.4)Cervix Uteri Oral Cavity & Pharynx Male 19 23.9 79.5 (47.9-124.2)Female 12 13.0 92.3 Female 10 10.4 96.5 (46.2-177.4)(47.7-161.3)Colon / Rectum Ovary Male 89.5 (72.2-109.8)92 102.8 Female 116 109.1 106.3 (87.9-127.5)Female 26 27.0 96.1 (62.8-140.9)**Esophagus Pancreas** Male 20 16.5 121.5 (74.2-187.7)Male 10 19.4 51.7 (24.7-95.0)94.5 Female 4 5.2 nc (nc-nc) Female 22 23.3 (59.2-143.2)Hodgkin Lymphoma **Prostate** Male Male 4.9 266.3 100.3 2 (nc-nc) 267 (88.6-113.0)nc Female 3 4.4 (nc-nc) nc Kidney & Renal Pelvis Stomach

Male

Male

Male

Uteri Corpus and Uterus, NOS

Female

Female

Male

Female

All Sites / Types

Female

<u>Testis</u>

Thyroid

22

14

7

1

13

63

849

853

17.3 127.4

11.5

8.2

6.5

21.2

887.3

874.8

51.3 122.7

122.3

85.3

nc

61.3

95.7

97.5

(79.8-193.0)

(66.8-205.1)

(34.2-175.8)

(nc-nc)

(32.6-104.8)

(94.3-157.0)

(89.4-102.3)

(91.1-104.3)

•	Ohs = ohserved	case count.	Fxn = expected	case count

Male

Male

Male

Male

Lung and Bronchus

Male

Female

Female

Female

Female

Female

<u>Larynx</u>

Leukemia

24

16

9

4

20

10

12

5

122

111

Liver and Intrahepatic Bile Ducts

26.9

18.7

11.4

3.3

20.7

18.5

12.4

5.3

129.4

125.6

89.4

85.3

79.1

nc

96.6

54.2

96.7

95.1

94.3

88.4

(57.2-133.0)

(48.8-138.6)

(36.1-150.1)

(59.0-149.2)

(25.9-99.6)

(49.9-169.0)

(30.6-221.9)

(78.3-112.6)

(72.7-106.4)

(nc-nc)

SIR = standardized incidence ratio ((Obs / Exp) X 100);

 ^{95%} CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

Shading indicates the statistical significance of the SIR at 95% level of probability;

[•] nc = The SIR and 95% CI were not calculated when Obs < 5;

Chilmark
Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

			•	•	vith Standardized Inciden	-			050/ 01
DI 11 11.	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>	M I (CI)	<u>Obs</u>	<u>Ехр</u>	<u>SIR</u>	<u>95% CI</u>
Bladder, Urinary	_			, ,	Melanoma of Skin				, ,
Male	1	1.4	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
Brain and Other		-	<u>n</u>		Multiple Myeloma				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					Non-Hodgkin Lympl	<u>noma</u>			
Male	0	0.0	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	6	4.2	141.7	(51.8-308.5)	Female	1	0.5	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Phary	<u>nx</u>			
					Male	1	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Colon / Rectum					<u>Ovary</u>				
Male	1	2.0	nc	(nc-nc)					
Female	1	1.6	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Esophagus					<u>Pancreas</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Hodgkin Lymphoma			<u>Prostate</u>						
Male	0	0.1	nc	(nc-nc)	Male	7	5.4	129.0	(51.7-265.7)
Female	0	0.1	nc	(nc-nc)					
Kidney & Renal	<u>Pelvis</u>				<u>Stomach</u>				
Male	2	0.5	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Liver and Intrah	epatic E	Bile Ducts	<u> </u>		Uteri Corpus and Ut	erus, NOS	1		
Male	0	0.3	nc	(nc-nc)					
Female	0	0.1	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
Lung and Brond	Lung and Bronchus				All Sites / Types				
Male	2	2.5	nc	(nc-nc)	Male	16	17.6	90.8	(51.9-147.5)
Female	3	1.9	nc	(nc-nc)	Female	14	13.8	101.1	(55.2-169.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Clarksburg
Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

Oho Eyn CID 0E0/ CI Oho Eyn CID 0E	:0/ CI
·	<u>% CI</u>
<u>Melanoma of Skin</u> Male 3 2.2 nc (nc-nc) Male 0 1.2 nc (n	امم مر
, ,	ic-nc)
	ıc-nc)
Brain and Other Nervous System Multiple Myeloma	
	ıc-nc)
	ıc-nc)
<u>Breast</u> <u>Non-Hodgkin Lymphoma</u>	
	ıc-nc)
Female 3 7.8 nc (nc-nc) Female 2 1.0 nc (n	ıc-nc)
Cervix Uteri Oral Cavity & Pharynx	
Male 0 0.9 nc (n	ıc-nc)
Female 0 0.3 nc (nc-nc) Female 0 0.4 nc (nc-nc)	ıc-nc)
<u>Colon / Rectum</u> <u>Ovary</u>	
Male 2 3.3 nc (nc-nc)	
Female 3 3.0 nc (nc-nc) Female 0 0.8 nc (n	ıc-nc)
<u>Esophagus</u> <u>Pancreas</u>	
Male 1 0.6 nc (nc-nc) Male 0 0.6 nc (n	ıc-nc)
Female 0 0.1 nc (nc-nc) Female 0 0.6 nc (n	ıc-nc)
Hodgkin Lymphoma Prostate	
Male 1 0.2 nc (nc-nc) Male 7 9.7 72.5 (29.0-1-	49.3)
Female 0 0.1 nc (nc-nc)	
Kidney & Renal Pelvis Stomach	
Male 1 0.9 nc (nc-nc) Male 0 0.6 nc (n	ıc-nc)
Female 0 0.6 nc (nc-nc) Female 0 0.3 nc (n	ıc-nc)
<u>Larynx</u> <u>Testis</u>	
•	ıc-nc)
Female 0 0.1 nc (nc-nc)	
<u>Leukemia</u> <u>Thyroid</u>	
	ıc-nc)
Female 0 0.5 nc (nc-nc) Female 1 0.7 nc (n	ıc-nc)
<u>Liver and Intrahepatic Bile Ducts</u> <u>Uteri Corpus and Uterus, NOS</u>	,
Male 0 0.4 nc (nc-nc)	
	ıc-nc)
Lung and Bronchus All Sites / Types	-,
Male 6 4.3 138.4 (50.5-301.2) Male 26 30.1 86.3 (56.4-1)	26.4)
Female 5 3.6 138.3 (44.6-322.8) Female 21 25.8 81.5 (50.5-1)	

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

ClintonObserved and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

			•		with Standardized Incide				250/ 21
	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
Bladder, Urinar					Melanoma of Skin				, ,
Male	13	14.2	91.6	(48.7-156.6)	Male	3	7.6	nc	(nc-nc)
Female	4	5.8	nc	(nc-nc)	Female	7	6.6	105.4	(42.2-217.3)
Brain and Other		-	<u>n</u>		Multiple Myeloma				
Male	3	2.7	nc	(nc-nc)	Male	3	2.0	nc	(nc-nc)
Female	2	2.6	nc	(nc-nc)	Female	1	1.9	nc	(nc-nc)
<u>Breast</u>					Non-Hodgkin Lym	<u>ohoma</u>			
Male	0	0.4	nc	(nc-nc)	Male	7	7.3	95.9	(38.4-197.6)
Female	47	56.4	83.3	(61.2-110.8)	Female	5	7.5	67.0	(21.6-156.4)
Cervix Uteri					Oral Cavity & Phar	<u>ynx</u>			
					Male	8	5.2	154.1	(66.4-303.7)
Female	6	2.5	243.0	(88.7-528.9)	Female	1	2.9	nc	(nc-nc)
Colon / Rectum					<u>Ovary</u>				
Male	19	21.4	88.9	(53.5-138.8)					
Female	23	24.2	95.2	(60.3-142.8)	Female	11	6.1	181.7	(90.6-325.1)
Esophagus					<u>Pancreas</u>				
Male	6	3.5	173.6	(63.4-377.9)	Male	2	4.0	nc	(nc-nc)
Female	3	1.1	nc	(nc-nc)	Female	4	5.1	nc	(nc-nc)
Hodgkin Lymph	<u>noma</u>				<u>Prostate</u>				
Male	3	1.2	nc	(nc-nc)	Male	46	55.5	82.9	(60.7-110.5)
Female	1	1.1	nc	(nc-nc)					
Kidney & Renal	<u>Pelvis</u>				<u>Stomach</u>				
Male	3	5.8	nc	(nc-nc)	Male	4	3.6	nc	(nc-nc)
Female	9	4.1	218.2	(99.6-414.2)	Female	0	2.6	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	3	2.4	nc	(nc-nc)	Male	0	2.2	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	1	4.5	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	4	4.2	nc	(nc-nc)	Female	4	5.2	nc	(nc-nc)
Liver and Intrah	epatic E	Bile Duct	<u>s</u>		Uteri Corpus and L	Jterus, NO	<u>)S</u>		
Male	3	2.7	nc	(nc-nc)					
Female	0	1.2	nc	(nc-nc)	Female	6	11.3	53.1	(19.4-115.5)
Lung and Brond	<u>chus</u>				All Sites / Types				
Male	33	26.8	123.2	(84.8-173.0)	Male	172	187.3	91.8	(78.6-106.6)
Female	20	27.1	73.7	(45.0-113.8)	Female	173	195.0	88.7	(76.0-102.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Cohasset
Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

			-		with Standardized inclu				050/ 01
Diaddan Halman	<u>Obs</u>	<u>Ехр</u>	<u>SIR</u>	<u>95% CI</u>	Malanana af Chia	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
Bladder, Urinar	_			(71.00101)	Melanoma of Skin				(,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Male 	12	8.6	139.2	(71.8-243.1)	Male	7	4.6	151.7	(60.8-312.5)
Female	3	3.2	nc	(nc-nc)	Female	16	3.7	430.3	(245.8-698.8)
Brain and Othe	r Nervou	-	<u>m</u>		Multiple Myeloma				
Male	2	1.6	nc	(nc-nc)	Male	3	1.3	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<u>Breast</u>					Non-Hodgkin Lym	<u>iphoma</u>			
Male	0	0.3	nc	(nc-nc)	Male	5	4.4	113.8	(36.7-265.6)
Female	36	33.4	107.9	(75.6-149.4)	Female	3	4.1	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pha	<u>rynx</u>			
					Male	6	3.4	177.0	(64.6-385.3)
Female	2	1.4	nc	(nc-nc)	Female	2	1.6	nc	(nc-nc)
Colon / Rectum	<u> </u>				<u>Ovary</u>				
Male	19	13.2	144.4	(86.9-225.5)					
Female	11	12.9	85.5	(42.6-153.0)	Female	4	3.5	nc	(nc-nc)
Esophagus					<u>Pancreas</u>				
Male	2	2.2	nc	(nc-nc)	Male	2	2.5	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	1	2.7	nc	(nc-nc)
Hodgkin Lymph	<u>noma</u>				<u>Prostate</u>				
Male	0	0.6	nc	(nc-nc)	Male	38	36.1	105.3	(74.5-144.5)
Female	0	0.5	nc	(nc-nc)					
Kidney & Renal	Pelvis				Stomach .				
Male	4	3.7	nc	(nc-nc)	Male	1	2.2	nc	(nc-nc)
Female	1	2.3	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	1.5	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	5	2.7	186.5	(60.1-435.3)	Male	3	0.9	nc	(nc-nc)
Female	0	2.3	nc	(nc-nc)	Female	4	2.9	nc	(nc-nc)
Liver and Intrah	nepatic I	Bile Duct	is		Uteri Corpus and	Uterus, N	os		
Male	1	1.7	nc	(nc-nc)	•				
Female	3	0.6	nc	(nc-nc)	Female	5	6.8	73.3	(23.6-171.1)
Lung and Bron	<u>chus</u>				All Sites / Types				
Male	12	16.6	72.1	(37.2-126.0)	Male	133	116.7	114.0	(95.4-135.1)
Female	7	15.2	46.0	(18.4-94.9)	Female	108	110.0	98.2	(80.5-118.5)
				, ,					, ,

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Colrain
Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

			•		vith Standardized Incidend				050/ 01
DI 11 11.	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>	M I (OI)	<u>Obs</u>	<u>Ехр</u>	<u>SIR</u>	<u>95% CI</u>
Bladder, Urinar	_			, ,	Melanoma of Skin				, ,
Male	2	2.1	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	0	8.0	nc	(nc-nc)
Brain and Other	r Nervou	-	<u>n</u>		Multiple Myeloma				
Male	0	0.4	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
<u>Breast</u>					Non-Hodgkin Lymph	<u>noma</u>			
Male	0	0.1	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	8	6.7	119.7	(51.5-235.8)	Female	0	8.0	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Phary	<u>1X</u>			
					Male	0	8.0	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
Colon / Rectum	_				<u>Ovary</u>				
Male	2	3.2	nc	(nc-nc)					
Female	3	2.3	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
Esophagus					<u>Pancreas</u>				
Male	0	0.5	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	3	0.5	nc	(nc-nc)
Hodgkin Lymph	<u>noma</u>				<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	4	8.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)					
Kidney & Renal	<u>Pelvis</u>				<u>Stomach</u>				
Male	0	0.9	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	2	0.5	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	1	0.7	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Liver and Intrah	nepatic E	Bile Ducts	<u> </u>		Uteri Corpus and Ut	erus, NOS	<u>.</u>		
Male	1	0.4	nc	(nc-nc)					
Female	0	0.1	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
Lung and Brone	<u>chus</u>				All Sites / Types				
Male	4	4.0	nc	(nc-nc)	Male	18	27.8	64.8	(38.4-102.4)
Female	6	2.8	210.8	(77.0-458.8)	Female	28	21.3	131.7	(87.5-190.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Concord

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>		and Exped	ted Case Counts, 95% CI	with Standardized Incide	ence Rati Obs	os, 1999-20 <u>Exp</u>	SIR	<u>95% CI</u>
Bladder, Urina		<u>Ехр</u>	SIIX	<u>7370 CI</u>	Melanoma of Skin		LAP	<u> 3111</u>	73 /0 CI
Male	18	23.1	77.9	(46.2-123.2)	Male	24	12.1	198.4	(127.1-295.2)
Female	10	7.7	129.6	(62.0-238.3)	Female	19		218.1	(127.1 275.2)
Brain and Othe				(02.0 230.0)	Multiple Myeloma	17	0.7	210.1	(131.2 310.0)
Male	4	4.1	nc	(nc-nc)	Male	6	3 3	179.3	(65.5-390.3)
Female	4	3.4	nc	(nc-nc)	Female	2	2.5	nc	(nc-nc)
<u>Breast</u>		0.1	110	(110 110)	Non-Hodgkin Lym		2.0	110	(110 110)
Male	1	0.7	nc	(nc-nc)	Male	14	11.6	120.9	(66.0-202.8)
Female	104	80.1	129.9	(106.1-157.4)	Female	13		132.2	(70.3-226.1)
Cervix Uteri				,	Oral Cavity & Pha				(
					Male	9	8.7	103.4	(47.2-196.2)
Female	4	3.2	nc	(nc-nc)	Female	7	4.0	176.0	(70.5-362.6)
Colon / Rectun	<u>1</u>				<u>Ovary</u>				
Male	27	34.9	77.3	(51.0-112.5)					
Female	30	31.9	94.2	(63.5-134.4)	Female	5	8.4	59.3	(19.1-138.4)
Esophagus					<u>Pancreas</u>				
Male	2	5.8	nc	(nc-nc)	Male	3	6.6	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)	Female	10	6.7	149.0	(71.3-274.0)
Hodgkin Lymp	<u>homa</u>				<u>Prostate</u>				
Male	4	1.6	nc	(nc-nc)	Male	103	93.8	109.8	(89.6-133.2)
Female	1	1.1	nc	(nc-nc)					
Kidney & Rena	<u>I Pelvis</u>				<u>Stomach</u>				
Male	5	9.5	52.8	(17.0-123.3)	Male	2	5.9	nc	(nc-nc)
Female	10	5.6	178.0	(85.2-327.4)	Female	3	3.4	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	3	4.0	nc	(nc-nc)	Male	5	2.7	187.1	(60.3-436.6)
Female	1	1.0	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	7	7.0	100.1	(40.1-206.3)	Male	2	2.3	nc	(nc-nc)
Female	3	5.5	nc	(nc-nc)	Female	5	6.5	77.2	(24.9-180.1)
Liver and Intra	•			, ,	Uteri Corpus and	Uterus, N	<u>NOS</u>		
Male	4	4.4	nc	(nc-nc)		00	44.4	1017	(7404070)
Female	. 4	1.6	nc	(nc-nc)	Female	20	16.4	121.7	(74.3-187.9)
Lung and Bron		42.0	F2.4	(22.2.70.7)	All Sites / Types	200	207.4	01.4	(01 0 100 7)
Male	23	43.9	52.4	(33.2-78.6)	Male	280	306.4	91.4	(81.0-102.7)
Female	23	36.6	62.9	(39.9-94.4)	Female	289	265.5	108.9	(96.7-122.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Conway

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003 95% CI Obs **Exp** SIR <u>Obs</u> <u>Exp</u> <u>SIR</u> 95% CI Bladder, Urinary Melanoma of Skin Male 0 1.7 (nc-nc) Male 1 1.1 nc (nc-nc) nc 0 Female 0.5 nc (nc-nc) Female 1 8.0 (nc-nc) nc Brain and Other Nervous System Multiple Myeloma Male Male 0 0.3 1 0.4 nc (nc-nc) nc (nc-nc) 0 0 0.3 Female 0.2 Female nc (nc-nc) nc (nc-nc) **Breast** Non-Hodgkin Lymphoma 0 0.1 Male (nc-nc) Male 1 1.0 nc (nc-nc) nc Female 4 7.1 (nc-nc) Female 0 8.0 (nc-nc) nc nc Cervix Uteri Oral Cavity & Pharynx Male 1 8.0 (nc-nc) nc Female 1 0.3 Female 1 0.3 (nc-nc) nc (nc-nc) nc Colon / Rectum Ovary Male 2 2.7 (nc-nc) nc Female 4 2.2 nc (nc-nc) Female 0 0.7 nc (nc-nc) **Pancreas Esophagus** 0 Male 0 0.5 nc (nc-nc) Male 0.5 nc (nc-nc) Female 0 0.1 nc (nc-nc) Female 0 0.5 nc (nc-nc) Hodgkin Lymphoma **Prostate** Male 0 0.2 Male 9 7.6 119.1 (54.3-226.0) (nc-nc) nc 0 Female 0.1 (nc-nc) nc Kidney & Renal Pelvis **Stomach** 0 Male 1 8.0 Male 0.5 (nc-nc) nc (nc-nc) nc 0 Female 0 Female 0.2 0.4 nc (nc-nc) nc (nc-nc) <u>Larynx</u> **Testis** 0 Male 1 0.3 0.3 nc (nc-nc) Male nc (nc-nc) Female 0 0.1 (nc-nc) nc **Leukemia Thyroid** 0 0 0.2 Male 0.6 (nc-nc) Male nc (nc-nc) nc Female 1 0.4 Female 0 0.7 (nc-nc) (nc-nc) nc nc Uteri Corpus and Uterus, NOS Liver and Intrahepatic Bile Ducts Male 0 0.4 (nc-nc) nc Female 0 0.1 0 1.4 nc (nc-nc) Female nc (nc-nc) Lung and Bronchus All Sites / Types Male 0 Male 20 24.7 8.08 (49.3-124.8) 3.4 (nc-nc) nc 2 2.7 Female nc (nc-nc) Female 17 21.7 78.5 (45.7-125.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Cummington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003 95% CI Obs **Exp** SIR <u>Obs</u> <u>Exp</u> <u>SIR</u> 95% CI Bladder, Urinary Melanoma of Skin Male 2 0.9 (nc-nc) Male 0 0.5 nc (nc-nc) nc 0 Female 0.3 nc (nc-nc) Female 0 0.4 (nc-nc) nc Brain and Other Nervous System Multiple Myeloma Male 0 Male 0 0.1 0.2 nc (nc-nc) nc (nc-nc) 1 0.2 Female 1 0.1 Female nc (nc-nc) nc (nc-nc) **Breast** Non-Hodgkin Lymphoma 0 0.0 0.5 Male (nc-nc) Male 1 nc (nc-nc) nc Female 3 3.7 (nc-nc) Female 0 0.4 (nc-nc) nc nc Cervix Uteri Oral Cavity & Pharynx 0 Male 0.4 (nc-nc) nc Female 0 0.2 Female 1 0.2 (nc-nc) nc (nc-nc) nc Colon / Rectum Ovary Male 1 1.5 (nc-nc) nc Female 1 1.3 nc (nc-nc) Female 1 0.4 nc (nc-nc) **Pancreas Esophagus** 0 0 Male 0.2 nc (nc-nc) Male 0.3 nc (nc-nc) Female 0 0.1 nc (nc-nc) Female 0 0.3 nc (nc-nc) Hodgkin Lymphoma **Prostate** Male 0 0.1 Male 2 4.0 (nc-nc) nc (nc-nc) nc Female 1 0.1 (nc-nc) nc Kidney & Renal Pelvis **Stomach** 0 Male 2 0.4 Male 0.2 (nc-nc) nc (nc-nc) nc 0 (nc-nc) Female 0 Female 0.1 0.2 nc (nc-nc) nc <u>Larynx</u> <u>Testis</u> 0 Male 0 0.2 0.2 nc (nc-nc) Male nc (nc-nc) Female 0 0.0 nc (nc-nc) **Leukemia Thyroid** 1 0 0.1 Male 0.3 (nc-nc) Male nc (nc-nc) nc Female 0 0.2 Female 0 0.4 (nc-nc) (nc-nc) nc nc Uteri Corpus and Uterus, NOS **Liver and Intrahepatic Bile Ducts** Male 0 0.2 (nc-nc) nc Female 0 0.1 1 0.7 nc (nc-nc) Female nc (nc-nc) Lung and Bronchus All Sites / Types Male 1 1.9 Male 10 75.8 (36.3-139.4) (nc-nc) 13.2 nc 2 12 100.8 Female 1.6 nc (nc-nc) Female 11.9 (52.0-176.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

DaltonObserved and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

			•		With Standardized inclu				OEO/ CI
Diaddon Ilvinos	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>	Malanama of Chin	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
Bladder, Urinar		0.1	100.1	(50.0.00(.4)	Melanoma of Skin	44	4.0	050 ((100 0 4/0 0)
Male	10	8.1	123.1	(58.9-226.4)	Male	11	4.3	258.6	(128.9-462.8)
Female	3	3.2	nc	(nc-nc)	Female	2	3.6	nc	(nc-nc)
Brain and Othe		-	<u>m</u>		Multiple Myeloma				
Male	1	1.5	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<u>Breast</u>					Non-Hodgkin Lym	<u>phoma</u>			
Male	1	0.3	nc	(nc-nc)	Male	6	4.1	146.4	(53.4-318.6)
Female	30	32.3	92.9	(62.7-132.7)	Female	3	4.1	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Phar	<u>ynx</u>			
					Male	1	3.0	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	Female	0	1.6	nc	(nc-nc)
Colon / Rectum	<u>1</u>				<u>Ovary</u>				
Male	13	12.3	105.8	(56.3-180.9)					
Female	18	13.4	134.2	(79.5-212.1)	Female	3	3.4	nc	(nc-nc)
Esophagus					<u>Pancreas</u>				
Male	1	2.0	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	2	2.8	nc	(nc-nc)
Hodgkin Lymph	noma				<u>Prostate</u>				
Male	1	0.6	nc	(nc-nc)	Male	40	32.6	122.6	(87.6-166.9)
Female	0	0.5	nc	(nc-nc)					,
Kidney & Rena	l Pelvis			, ,	<u>Stomach</u>				
Male	5	3.3	150.8	(48.6-351.9)	Male	2	2.1	nc	(nc-nc)
Female	4	2.3	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
<u>Larynx</u>				, ,	<u>Testis</u>				, ,
Male	2	1.4	nc	(nc-nc)		3	1.0	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)					, ,
<u>Leukemia</u>				,	<u>Thyroid</u>				
Male	3	2.5	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	1	2.3	nc	(nc-nc)	Female	2	2.7	nc	(nc-nc)
Liver and Intrah				(Uteri Corpus and I				(1.0 1.0)
Male	1	1.6	nc	(nc-nc)	<u> </u>	<u> </u>	<u></u>		
Female	0	0.6	nc	(nc-nc)	Female	5	6.5	76.5	(24.7-178.5)
Lung and Bron				()	All Sites / Types	-	2.3		(
Male	15	15.5	97.0	(54.3-160.0)	Male	123	107.5	114.4	(95.1-136.5)
Female	18	15.3	117.4	(69.6-185.6)	Female	103	109.5	94.1	(76.8-114.1)
Tomaio	10	10.0		(37.3 100.0)	romaio	. 55	107.0	, 1. 1	(70.0 111.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Danvers

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	(Observed a	and Expect	ted Case Counts, v	vith Standardized Incide	nce Ratios	s, 1999-200	3	
	<u>Obs</u>	<u>Exp</u>	SIR	<u>95% CI</u>		<u>Obs</u>	<u>Ехр</u>	<u>SIR</u>	<u>95% CI</u>
Bladder, Urina	<u>ıry</u>				Melanoma of Skin				
Male	42	31.0	135.7	(97.8-183.4)	Male	19	16.0	118.7	(71.5-185.4)
Female	11	12.0	91.6	(45.7-164.0)	Female	9	13.5	66.8	(30.5-126.8)
Brain and Oth	er Nervo	us Syster	<u>n</u>		Multiple Myeloma				
Male	6	5.5	109.5	(40.0-238.3)	Male	3	4.5	nc	(nc-nc)
Female	6	5.2	115.8	(42.3-252.0)	Female	2	3.9	nc	(nc-nc)
<u>Breast</u>					Non-Hodgkin Lym	<u>phoma</u>			
Male	1	1.0	nc	(nc-nc)	Male	19	15.4	123.2	(74.2-192.5)
Female	127	119.2	106.6	(88.8-126.8)	Female	14	15.3	91.5	(50.0-153.5)
Cervix Uteri					Oral Cavity & Pha	<u>rynx</u>			
					Male	4	11.3	nc	(nc-nc)
Female	5	5.0	99.6	(32.1-232.4)	Female	7	6.0	115.9	(46.4-238.9)
Colon / Rectur	<u>m</u>				<u>Ovary</u>				
Male	68	46.6	146.0	(113.3-185.1)					
Female	45	49.6	90.7	(66.1-121.4)	Female	17	12.7	134.1	(78.0-214.7)
Esophagus					<u>Pancreas</u>				
Male	7	7.6	92.0	(36.9-189.6)	Male	11	8.8	125.1	(62.4-223.8)
Female	4	2.4	nc	(nc-nc)	Female	8	10.5	76.2	(32.8-150.2)
Hodgkin Lymp	<u>ohoma</u>				<u>Prostate</u>				
Male	2	2.2	nc	(nc-nc)	Male	116	124.3	93.4	(77.1-112.0)
Female	3	2.0	nc	(nc-nc)					
Kidney & Rena	al Pelvis				<u>Stomach</u>				
Male	16	12.5	128.1	(73.2-208.0)	Male	7	7.8	89.4	(35.8-184.2)
Female	7	8.6	81.5	(32.7-168.0)	Female	3	5.3	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	5.3	nc	(nc-nc)	Male	4	3.7	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	13	9.4	138.8	(73.9-237.5)	Male	3	3.1	nc	(nc-nc)
Female	10	8.5	117.8	(56.4-216.6)	Female	8	10.3	77.9	(33.5-153.5)
Liver and Intra	hepatic	Bile Duct	<u>s</u>		Uteri Corpus and	Uterus, N	<u>os</u>		
Male	6	5.8	103.3	(37.7-224.8)					
Female	1	2.4	nc	(nc-nc)	Female	16	24.1	66.3	(37.9-107.6)
Lung and Bro	<u>nchus</u>				All Sites / Types				
Male	65	58.8	110.6	(85.3-140.9)	Male	443	407.5	108.7	(98.8-119.3)
Female	73	56.5	129.2	(101.3-162.5)	Female	416	405.2	102.7	(93.0-113.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Dartmouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

			-		With Standardized inclu				000/ 01
BI II II:	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
Bladder, Urina				(, , , , , , , , , , , , , , , , , , ,	Melanoma of Skin	='			(,,,,,,,,,,,)
Male	35	36.5	95.9	(66.8-133.3)	Male	14	19.1	73.2	(40.0-122.8)
Female	17	13.3	127.7	(74.4-204.5)	Female	17	15.1	112.6	(65.5-180.3)
Brain and Oth	er Nerv	ous Syster			Multiple Myeloma				
Male	7	6.6	105.4	(42.2-217.1)	Male	7	5.3	132.7	(53.2-273.4)
Female	6	5.8	103.5	(37.8-225.3)	Female	10	4.4	229.4	(109.8-422.0)
<u>Breast</u>					Non-Hodgkin Lym	<u>iphoma</u>			
Male	0	1.1	nc	(nc-nc)	Male	15	18.5	81.2	(45.4-133.9)
Female	115	133.2	86.4	(71.3-103.7)	Female	17	17.1	99.6	(58.0-159.4)
Cervix Uteri					Oral Cavity & Pha	<u>rynx</u>			
					Male	20	13.6	147.5	(90.1-227.9)
Female	7	5.5	126.9	(50.8-261.4)	Female	4	6.8	nc	(nc-nc)
Colon / Rectur	<u>m</u>				<u>Ovary</u>				
Male	77	55.2	139.6	(110.1-174.5)					
Female	42	54.9	76.4	(55.1-103.3)	Female	11	14.2	77.4	(38.6-138.5)
Esophagus					<u>Pancreas</u>				
Male	3	9.0	nc	(nc-nc)	Male	13	10.4	124.7	(66.3-213.2)
Female	1	2.6	nc	(nc-nc)	Female	14	11.6	120.2	(65.6-201.7)
Hodgkin Lymp	ohoma				<u>Prostate</u>				
Male	4	3.0	nc	(nc-nc)	Male	178	145.9	122.0	(104.7-141.3)
Female	2	2.4	nc	(nc-nc)					,
Kidney & Rena	al Pelvi	<u>s</u>			<u>Stomach</u>				
Male	27	14.8	182.4	(120.2-265.4)	Male	11	9.3	118.4	(59.0-211.9)
Female	10	9.6	104.1	(49.9-191.5)	Female	10	5.8	173.3	(83.0-318.8)
<u>Larynx</u>				,	<u>Testis</u>				,
Male	7	6.3	111.6	(44.7-230.0)	 Male	3	4.8	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)					, ,
<u>Leukemia</u>				(/	<u>Thyroid</u>				
Male	10	11.2	89.2	(42.7-164.0)	Male	1	3.7	nc	(nc-nc)
Female	7	9.4	74.5	(29.8-153.5)	Female	10	11.5	87.2	(41.7-160.3)
Liver and Intra				(=::::	Uteri Corpus and				(**************************************
Male	5	6.9	2 72.5	(23.4-169.1)	<u> </u>	0.0.007.	<u></u>		
Female	2	2.7	nc	(nc-nc)	Female	26	27.2	95.8	(62.5-140.3)
Lung and Bro				(/	All Sites / Types		_		(4 4 1 1 1 2 1 9)
Male	63	69.1	91.1	(70.0-116.6)	Male	524	482 8	108.5	(99.4-118.2)
Female	54	63.3	85.4	(64.1-111.4)	Female	420	452.0	92.9	(84.2-102.2)
i Ciliaic	57	00.0	55.7	(51.1111.17)	i citiale	120	102.0	12.1	(01.2 102.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Dedham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003 <u>Obs</u> **Exp** SIR 95% CI Obs <u> Exp</u> SIR 95% CI Bladder, Urinary Melanoma of Skin Male 32 29.6 108.1 (73.9-152.6) Male 14 15.2 92.1 (50.3-154.6)Female 11 10.8 102.0 (50.8-182.4)Female 13 12.2 106.4 (56.6-181.9)**Brain and Other Nervous System** Multiple Myeloma Male 7 165.4 Male 3 5.2 nc (nc-nc) 4.2 (66.2-340.7)2 4.7 Female 4 3.5 Female nc (nc-nc) nc (nc-nc) Non-Hodgkin Lymphoma **Breast** Male 1 0.9 nc (nc-nc) Male 15 14.7 102.2 (57.1-168.5)Female 124 107.3 115.5 (96.1-137.8) Female 10 13.8 72.6 (34.8-133.5)Cervix Uteri Oral Cavity & Pharynx Male 13 10.6 122.8 (65.3-210.1)3 Female 1 5.5 Female 4.5 nc (nc-nc) nc (nc-nc) Colon / Rectum Ovary Male (70.1-130.5)43 44.4 96.9 Female 43 44.1 97.5 (70.5-131.3)Female 14 11.4 122.8 (67.1-206.0)**Esophagus Pancreas** Male 5 9 107.6 7.2 69.6 (22.4-162.5) Male 8.4 (49.1-204.3)117.2 Female 2 2.1 nc (nc-nc) Female 11 9.4 (58.4-209.7)Hodgkin Lymphoma **Prostate** Male Male 116.7 106.3 4 2.1 (nc-nc) 124 (88.4-126.7)nc Female 3 1.8 nc (nc-nc) Kidney & Renal Pelvis Stomach (46.1-211.0) Male 15 11.8 127.4 (71.2-210.1) Male 8 7.5 107.1 2 Female Female 10 7.8 128.6 (61.6-236.5) 4.6 nc (nc-nc) <u>Larynx</u> <u>Testis</u> 7 Male 3 187.0 (74.9 - 385.3)5.0 nc (nc-nc) Male 3.7 Female 0 1.4 nc (nc-nc) **Leukemia Thyroid** 7 3 Male 9.0 78.1 (31.3-161.0)Male 2.9 nc (nc-nc) Female 8 105.1 (45.3-207.2) Female 9 9.3 96.8 (44.2-183.7)7.6 **Liver and Intrahepatic Bile Ducts** Uteri Corpus and Uterus, NOS Male 7 5.5 128.3 (51.4-264.3) Female 3 2.1 nc (nc-nc) Female 23 22.0 104.6 (66.3-157.0)Lung and Bronchus All Sites / Types Male 55.9 91.3 (68.0-120.1) Male 406 386.3 105.1 (95.1-115.8) 51

• Obs = observed case count; Exp = expected case count;

51.5

Female

65

- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

(97.5-161.0)

- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

126.3

Female

386

364.8 105.8

(95.5-116.9)

Deerfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

			•		vith Standardized Inciden				050/ 01
	<u>Obs</u>	<u>Exp</u>	SIR	<u>95% CI</u>		<u>Obs</u>	<u>Ехр</u>	<u>SIR</u>	<u>95% CI</u>
Bladder, Urinar					Melanoma of Skin				
Male	3	5.6	nc	(nc-nc)	Male	7	3.1	224.8	(90.1-463.3)
Female	5	1.9	257.1	(82.9-600.1)	Female	2	2.4	nc	(nc-nc)
Brain and Othe	r Nervou	us Syster	<u>n</u>		<u>Multiple Myeloma</u>				
Male	1	1.1	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Breast</u>					Non-Hodgkin Lympl	<u>noma</u>			
Male	0	0.2	nc	(nc-nc)	Male	2	2.9	nc	(nc-nc)
Female	16	21.5	74.3	(42.5-120.7)	Female	2	2.6	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Phary	<u>nx</u>			
					Male	1	2.3	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
Colon / Rectum	<u>1</u>				<u>Ovary</u>				
Male	6	8.7	69.1	(25.2-150.5)					
Female	7	8.0	87.9	(35.2-181.1)	Female	1	2.2	nc	(nc-nc)
Esophagus					<u>Pancreas</u>				
Male	0	1.4	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	1.7	nc	(nc-nc)
Hodgkin Lympl	<u>homa</u>				<u>Prostate</u>				
Male	1	0.4	nc	(nc-nc)	Male	21	23.2	90.5	(56.0-138.4)
Female	0	0.4	nc	(nc-nc)					
Kidney & Rena	<u>l Pelvis</u>				<u>Stomach</u>				
Male	2	2.4	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
Female	0	1.5	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	1	1.0	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	4	1.8	nc	(nc-nc)	Male	2	0.6	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	Female	1	2.0	nc	(nc-nc)
Liver and Intral	nepatic I	Bile Ducts	<u>s</u>		Uteri Corpus and Ut	erus, NOS	<u>.</u>		
Male	0	1.1	nc	(nc-nc)					
Female	0	0.4	nc	(nc-nc)	Female	3	4.4	nc	(nc-nc)
Lung and Bron	<u>chus</u>				All Sites / Types				
Male	5	10.8	46.2	(14.9-107.7)	Male	65	76.6	84.9	(65.5-108.2)
Female	5	9.5	52.8	(17.0-123.2)	Female	47	69.8	67.4	(49.5-89.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Dennis
Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	(Observed a	ind Expect	ted Case Counts, v	with Standardized Incid	lence Rati	os, 1999-20	03	
	<u>Obs</u>	<u>Ехр</u>	SIR	<u>95% CI</u>		<u>Obs</u>	<u>Ехр</u>	<u>SIR</u>	<u>95% CI</u>
Bladder, Urina	<u>iry</u>				Melanoma of Skin	<u>.</u>			
Male	36	33.1	108.8	(76.2-150.6)	Male	30	14.6	205.4	(138.6-293.3)
Female	16	11.1	143.6	(82.0-233.1)	Female	20	10.6	188.7	(115.2-291.4)
Brain and Oth	er Nervo	us Syster	<u>n</u>		Multiple Myeloma				
Male	3	4.5	nc	(nc-nc)	Male	4	4.6	nc	(nc-nc)
Female	4	4.1	nc	(nc-nc)	Female	4	3.7	nc	(nc-nc)
<u>Breast</u>					Non-Hodgkin Lym	<u>iphoma</u>			
Male	2	1.0	nc	(nc-nc)	Male	18	14.6	123.4	(73.1-195.1)
Female	113	100.3	112.6	(92.8-135.4)	Female	16	13.6	117.5	(67.1-190.8)
Cervix Uteri					Oral Cavity & Pha	<u>rynx</u>			
					Male	12	10.2	117.9	(60.9-206.0)
Female	5	3.6	138.0	(44.5-322.1)	Female	8	5.3	152.2	(65.5-299.9)
Colon / Rectur	<u>m</u>				<u>Ovary</u>				
Male	42	48.4	86.8	(62.6-117.4)					
Female	46	45.4	101.4	(74.2-135.2)	Female	19	10.8	175.8	(105.8-274.5)
Esophagus					<u>Pancreas</u>				
Male	8	7.6	105.0	(45.2-206.9)	Male	8	9.1	87.8	(37.8-173.1)
Female	3	2.2	nc	(nc-nc)	Female	9	9.8	92.2	(42.1-175.0)
<u>Hodgkin Lym</u> r	<u>ohoma</u>				<u>Prostate</u>				
Male	1	1.5	nc	(nc-nc)	Male	173	126.2	137.1	(117.4-159.1)
Female	1	1.3	nc	(nc-nc)					
Kidney & Rena	al Pelvis				<u>Stomach</u>				
Male	12	11.9	101.1	(52.2-176.6)	Male	3	8.1	nc	(nc-nc)
Female	8	7.7	103.9	(44.7-204.7)	Female	3	4.7	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	2	5.2	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	9	9.0	100.2	(45.7-190.3)	Male	2	2.3	nc	(nc-nc)
Female	7	7.2	97.2	(38.9-200.3)	Female	6	6.8	87.9	(32.1-191.3)
Liver and Intra	hepatic	Bile Ducts	<u>S</u>		Uteri Corpus and	Uterus, N	<u>os</u>		
Male	5	5.4	92.0	(29.6-214.7)					
Female	1	2.2	nc	(nc-nc)	Female	21	21.1	99.4	(61.5-151.9)
Lung and Bro	<u>nchus</u>				All Sites / Types				
Male	48	61.5	78.1	(57.6-103.6)	Male	449	408.0	110.1	(100.1-120.7)
Female	58	53.3	108.9	(82.7-140.8)	Female	394	353.3	111.5	(100.8-123.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Dighton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003 <u>Obs</u> **Exp** <u>SIR</u> 95% CI Obs <u>Exp</u> <u>SIR</u> 95% CI Bladder, Urinary Melanoma of Skin Male 7 6.6 106.7 (42.8-219.9)Male 0 3.6 nc (nc-nc) 2 Female 2.3 nc (nc-nc) Female 3 2.9 nc (nc-nc) **Brain and Other Nervous System** Multiple Myeloma Male Male 4 1.3 nc (nc-nc) 1 1.0 nc (nc-nc) 1.1 1 8.0 Female 1 nc (nc-nc) Female nc (nc-nc) Non-Hodgkin Lymphoma **Breast** (158.9-570.5)Male 1 0.2 nc (nc-nc) Male 11 3.5 318.8 Female 31 25.0 124.2 (84.4-176.3) Female 3 3.0 nc (nc-nc) Cervix Uteri Oral Cavity & Pharynx Male 3 2.6 (nc-nc) nc 1.2 Female Female 1 (nc-nc) 1 1.1 nc (nc-nc) nc Colon / Rectum Ovary Male 10.0 (91.0-258.8)16 159.4 Female 8 9.5 84.7 (36.4-166.8)Female 1 2.6 nc (nc-nc) **Esophagus Pancreas** Male 0 2 1.7 nc (nc-nc) Male 1.9 nc (nc-nc) Female 1 0.5 nc (nc-nc) Female 2 2.0 nc (nc-nc) Hodgkin Lymphoma **Prostate** Male 0.5 Male 29 26.9 107.7 (72.1-154.7)1 (nc-nc) nc 0 Female 0.4 (nc-nc) nc Kidney & Renal Pelvis Stomach Male 2 2.8 Male 0 1.7 (nc-nc) nc (nc-nc) nc Female 3 1.7 Female 1 1.0 nc (nc-nc) nc (nc-nc) **Larynx Testis** 2 0 Male 1.2 nc (nc-nc) Male 1.0 nc (nc-nc) Female 0 0.3 nc (nc-nc) <u>Leukemia</u> **Thyroid** 3 0.7 Male 2.1 nc (nc-nc) Male 1 nc (nc-nc) Female 1 1.7 Female 5 2.4 210.3 (67.8-490.8)nc (nc-nc) **Liver and Intrahepatic Bile Ducts** Uteri Corpus and Uterus, NOS Male 1 1.3 nc (nc-nc) Female 2 2 0.5 nc (nc-nc) Female 5.0 nc (nc-nc) Lung and Bronchus All Sites / Types Male 12.5 119.5 (66.9-197.2) Male 103 89.0 115.7 (94.4-140.3) 15 Female 12 11.1 108.2 (55.9-189.1)Female 87 82.1 106.0 (84.9-130.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

 ${\color{red} \textbf{Douglas}} \\ \textbf{Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003} \\$

			-		viin Standardized inciden				OE9/ CI
Bladder, Urinar	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>	Melanoma of Skin	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
Male	y 3	4.9	nc	(nc-nc)	Male	4	3.2	nc	(nc-nc)
Female	0	1.7	nc	(nc-nc)	Female	1	2.7		(nc-nc)
Brain and Othe				(HC-HC)	Multiple Myeloma	!	2.1	nc	(116-116)
Male		_	_	(no no)	Male	1	0.0	no	(no no)
	3	1.2	nc	(nc-nc)		1	0.8	nc	(nc-nc)
Female	2	1.0	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Breast</u>	0	0.0		(20, 20)	Non-Hodgkin Lympl		2.0		(20, 20)
Male	0	0.2	nc 120.2	(nc-nc)	Male	4	3.0	nc	(nc-nc)
Female	27	20.9	129.2	(85.1-188.0)	Female	1	2.4	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Phary		0.0		, ,
Famala	1	1 1		(Male	3	2.2	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	2	1.0	nc	(nc-nc)
Colon / Rectum	•	7.7	00 ((2/ 2 40/ /)	<u>Ovary</u>				
Male	7	7.7	90.6	(36.3-186.6)	Famala	1	2.2		(
Female	6	7.1	84.9	(31.0-184.8)	Female	1	2.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				, ,
Male	0	1.3	nc	(nc-nc)	Male	3	1.5	nc	(nc-nc)
Female	2	0.3	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
Hodgkin Lymph	<u>noma</u>				<u>Prostate</u>				
Male	0	0.6	nc	(nc-nc)	Male	15	19.9	75.3	(42.1-124.2)
Female	0	0.5	nc	(nc-nc)					
Kidney & Renal	Pelvis				<u>Stomach</u>				
Male	0	2.3	nc	(nc-nc)	Male	3	1.3	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	Female	1	8.0	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	2	0.9	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	1	1.8	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)	Female	2	2.5	nc	(nc-nc)
Liver and Intrah	<u>nepatic E</u>	Bile Ducts	<u> </u>		Uteri Corpus and Ut	erus, NOS	<u>i</u>		
Male	0	1.1	nc	(nc-nc)					
Female	0	0.4	nc	(nc-nc)	Female	5	4.0	125.0	(40.3-291.7)
Lung and Bron	<u>chus</u>				All Sites / Types				
Male	6	9.4	64.0	(23.4-139.3)	Male	60	70.0	85.7	(65.4-110.4)
Female	8	8.1	98.2	(42.3-193.5)	Female	64	66.4	96.3	(74.2-123.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

DoverObserved and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

			•		with Standardized Incide				c=0. c-
	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
Bladder, Urinai					Melanoma of Skin				
Male	4	6.2	nc	(nc-nc)	Male	3	3.5	nc	(nc-nc)
Female	0	1.8	nc	(nc-nc)	Female	7	2.5	276.6	(110.8-569.9)
Brain and Othe	r Nervou	us Syster	<u>m</u>		Multiple Myeloma				
Male	2	1.2	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	3	1.0	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Breast</u>					Non-Hodgkin Lymp	homa			
Male	0	0.2	nc	(nc-nc)	Male	4	3.3	nc	(nc-nc)
Female	22	22.8	96.4	(60.4-145.9)	Female	3	2.5	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Phary	<u>/nx</u>			
					Male	1	2.6	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	2	1.1	nc	(nc-nc)
Colon / Rectum	<u>1</u>				<u>Ovary</u>				
Male	10	9.6	103.9	(49.8-191.1)					
Female	8	7.2	110.9	(47.7-218.4)	Female	6	2.3	258.2	(94.3-562.1)
Esophagus					<u>Pancreas</u>				
Male	0	1.6	nc	(nc-nc)	Male	0	1.8	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
Hodgkin Lymp	<u>homa</u>				<u>Prostate</u>				
Male	0	0.5	nc	(nc-nc)	Male	39	27.2	143.6	(102.1-196.3)
Female	0	0.4	nc	(nc-nc)					
Kidney & Rena	l Pelvis				Stomach				
Male	1	2.8	nc	(nc-nc)	Male	5	1.6	312.8	(100.8-729.9)
Female	2	1.5	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	1	1.2	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	1	2.0	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	Female	4	2.1	nc	(nc-nc)
Liver and Intra	hepatic I	Bile Duct	<u>s</u>		Uteri Corpus and U	terus, NOS	<u>S</u>		
Male	0	1.3	nc	(nc-nc)					
Female	0	0.4	nc	(nc-nc)	Female	4	4.7	nc	(nc-nc)
Lung and Bron	<u>ichus</u>				All Sites / Types				
Male	5	12.2	40.9	(13.2-95.5)	Male	80	86.7	92.3	(73.2-114.9)
Female	9	9.4	96.0	(43.8-182.2)	Female	76	70.4	108.0	(85.1-135.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Dracut
Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	(Observed a	and Expec	ted Case Counts, v	vith Standardized Incid		os, 1999-20	03	
	<u>Obs</u>	<u>Exp</u>	SIR	<u>95% CI</u>		<u>Obs</u>	<u>Ехр</u>	<u>SIR</u>	<u>95% CI</u>
Bladder, Urina	<u>iry</u>				Melanoma of Skir	<u>1</u>			
Male	28	25.9	108.3	(72.0-156.5)	Male	3	15.0	nc	(nc-nc)
Female	12	9.5	127.0	(65.5-221.8)	Female	12	12.8	93.8	(48.4-163.9)
Brain and Oth	er Nervo	ous Syste	<u>m</u>		Multiple Myeloma				
Male	7	5.5	126.9	(50.9-261.6)	Male	3	3.8	nc	(nc-nc)
Female	3	4.8	nc	(nc-nc)	Female	6	3.1	193.5	(70.6-421.1)
<u>Breast</u>					Non-Hodgkin Lyn	<u>nphoma</u>			
Male	0	0.8	nc	(nc-nc)	Male	10	14.1	70.7	(33.9-130.1)
Female	105	106.4	98.7	(80.7-119.5)	Female	15	12.8	117.2	(65.6-193.4)
Cervix Uteri					Oral Cavity & Pha	<u>rynx</u>			
					Male	11	10.6	104.2	(51.9-186.4)
Female	4	5.0	nc	(nc-nc)	Female	7	5.2	135.2	(54.2-278.6)
Colon / Rectu	<u>m</u>				<u>Ovary</u>				
Male	35	39.7	88.1	(61.3-122.5)					
Female	54	37.9	142.3	(106.9-185.7)	Female	17	11.1	153.4	(89.3-245.6)
Esophagus					<u>Pancreas</u>				
Male	9	6.7	134.9	(61.6-256.2)	Male	6	7.5	79.9	(29.2-173.9)
Female	4	1.8	nc	(nc-nc)	Female	9	8.1	111.6	(50.9-211.8)
Hodgkin Lymp	<u>ohoma</u>				<u>Prostate</u>				
Male	1	2.5	nc	(nc-nc)	Male	114	109.1	104.5	(86.2-125.5)
Female	2	2.1	nc	(nc-nc)					
Kidney & Rena	al Pelvis	<u>i</u>			Stomach Stomach				
Male	13	11.4	113.7	(60.5-194.4)	Male	6	6.6	90.6	(33.1-197.2)
Female	7	7.3	95.4	(38.2-196.6)	Female	4	3.9	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	7	4.7	148.2	(59.4-305.4)	Male	6	4.7	126.6	(46.2-275.6)
Female	3	1.3	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	8	8.6	92.8	(40.0-182.9)	Male	5	3.3	153.1	(49.4-357.4)
Female	3	7.1	nc	(nc-nc)	Female	9	11.0	82.1	(37.5-155.9)
Liver and Intra	hepatic	Bile Duct	<u>ts</u>		Uteri Corpus and	Uterus, N	<u> </u>		
Male	4	5.3	nc	(nc-nc)					
Female	2	1.9	nc	(nc-nc)	Female	30	21.4	140.2	(94.6-200.2)
Lung and Bro	nchus				All Sites / Types				
Male	63	50.6	124.5	(95.7-159.3)	Male	359	360.4	99.6	(89.6-110.5)
Female	52	47.0	110.6	(82.6-145.1)	Female	391	345.9	113.0	(102.1-124.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

DudleyObserved and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

			•		with Standardized Incid				050/ 01
Dladdor Urbs	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>	Molonoma of Clim	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
Bladder, Urinary		10.4	0/ 4	(20.4.1/4.0)	Melanoma of Skin		Г/		(20, 20)
Male	9	10.4	86.4	(39.4-164.0)	Male	3	5.6	nc 154.2	(nc-nc)
Female	3	3.6	nc	(nc-nc)	Female	7	4.5	156.2	(62.6-321.9)
Brain and Other				, ,	Multiple Myeloma		4.5		()
Male	1	2.0	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	0	1.7	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<u>Breast</u>	0	0.0		, ,	Non-Hodgkin Lym		5 4		()
Male	0	0.3	nc	(nc-nc)	Male	3	5.4	nc	(nc-nc)
Female	33	38.0	86.9	(59.8-122.0)	Female	5	4.7	105.3	(33.9-245.8)
Cervix Uteri					Oral Cavity & Pha				, ,
	•	4.7		, ,	Male	3	4.0	nc	(nc-nc)
Female	0	1.7	nc	(nc-nc)	Female	1	1.9	nc	(nc-nc)
Colon / Rectum		45.0		(<u>Ovary</u>				
Male	14	15.8	88.6	(48.4-148.7)			4.0	000 /	(100 0 101 1)
Female 	13	14.7	88.4	(47.0-151.2)	Female	9	4.0	223.6	(102.0-424.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	2.6	nc	(nc-nc)	Male	2	3.0	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	3	3.1	nc	(nc-nc)
Hodgkin Lympho	<u>oma</u>				<u>Prostate</u>				
Male	0	0.9	nc	(nc-nc)	Male	33	41.6	79.3	(54.6-111.4)
Female	1	0.8	nc	(nc-nc)					
Kidney & Renal					<u>Stomach</u>				
Male	2	4.3	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
Female	1	2.7	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	1	1.8	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
Female	2	0.5	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	3	3.3	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	1	2.6	nc	(nc-nc)	Female	3	3.7	nc	(nc-nc)
Liver and Intrahe	epatic Bi	<u>lle Ducts</u>			Uteri Corpus and	Uterus, NO	<u>os</u>		
Male	0	2.0	nc	(nc-nc)					
Female	0	0.7	nc	(nc-nc)	Female	9	7.6	117.8	(53.7-223.6)
Lung and Bronc	<u>hus</u>				All Sites / Types				
Male	12	19.7	60.8	(31.4-106.2)	Male	106	139.3	76.1	(62.3-92.1)
Female	15	17.3	86.9	(48.6-143.3)	Female	116	126.5	91.7	(75.7-109.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

DunstableObserved and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

			-		vith Standardized Inciden				
	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
Bladder, Urinary	,				Melanoma of Skin				
Male	0	2.1	nc	(nc-nc)	Male	4	1.4	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
Brain and Other	Nervous	System			Multiple Myeloma				
Male	0	0.5	nc	(nc-nc)	Male	2	0.3	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					Non-Hodgkin Lympl	<u>noma</u>			
Male	0	0.1	nc	(nc-nc)	Male	3	1.3	nc	(nc-nc)
Female	9	9.5	94.6	(43.2-179.7)	Female	0	1.0	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Phary	<u>nx</u>			
					Male	1	1.1	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	2	0.4	nc	(nc-nc)
Colon / Rectum					<u>Ovary</u>				
Male	0	3.4	nc	(nc-nc)					
Female	3	2.6	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.6	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Hodgkin Lympho	<u>oma</u>				<u>Prostate</u>				
Male	1	0.2	nc	(nc-nc)	Male	12	9.9	121.3	(62.6-211.9)
Female	0	0.2	nc	(nc-nc)					
Kidney & Renal I	<u>Pelvis</u>				<u>Stomach</u>				
Male	0	1.1	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	0	8.0	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
Liver and Intrahe	epatic Bil	e Ducts			Uteri Corpus and Ut	erus, NOS	<u>.</u>		
Male	0	0.5	nc	(nc-nc)					
Female	0	0.1	nc	(nc-nc)	Female	2	1.9	nc	(nc-nc)
Lung and Broncl	<u>hus</u>				All Sites / Types				
Male	4	4.3	nc	(nc-nc)	Male	32	32.0	99.9	(68.3-141.0)
Female	3	3.4	nc	(nc-nc)	Female	28	28.0	100.1	(66.5-144.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

DuxburyObserved and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	SIR	<u>95% CI</u>	
Bladder, Urinar	<u>y</u>				Melanoma of Skin					
Male	12	14.8	80.8	(41.7-141.2)	Male	22	8.4	260.5	(163.2-394.5)	
Female	6	5.4	110.7	(40.4-241.1)	Female	12	6.9	173.5	(89.6-303.1)	
Brain and Other Nervous System					Multiple Myeloma					
Male	2	3.1	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)	
Female	5	2.6	188.8	(60.9-440.7)	Female	3	1.8	nc	(nc-nc)	
<u>Breast</u>					Non-Hodgkin Lym	<u>phoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	8	7.9	100.9	(43.4-198.7)	
Female	57	61.7	92.4	(69.9-119.7)	Female	8	7.2	111.5	(48.0-219.8)	
Cervix Uteri					Oral Cavity & Phar	<u>ynx</u>				
					Male	2	6.4	nc	(nc-nc)	
Female	0	2.7	nc	(nc-nc)	Female	2	3.0	nc	(nc-nc)	
Colon / Rectum	1				<u>Ovary</u>					
Male	28	23.0	121.5	(80.7-175.6)						
Female	21	22.7	92.6	(57.3-141.5)	Female	5	6.4	77.8	(25.1-181.5)	
<u>Esophagus</u>					<u>Pancreas</u>					
Male	3	3.9	nc	(nc-nc)	Male	7	4.4	158.9	(63.6-327.3)	
Female	1	1.1	nc	(nc-nc)	Female	2	4.7	nc	(nc-nc)	
Hodgkin Lymph	<u>noma</u>				<u>Prostate</u>					
Male	1	1.2	nc	(nc-nc)	Male	105	63.7	164.9	(134.9-199.6)	
Female	2	1.0	nc	(nc-nc)						
Kidney & Renal	l Pelvis				<u>Stomach</u>					
Male	6	6.6	90.3	(33.0-196.5)	Male	1	3.9	nc	(nc-nc)	
Female	4	4.1	nc	(nc-nc)	Female	1	2.4	nc	(nc-nc)	
<u>Larynx</u>					<u>Testis</u>					
Male	2	2.8	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)	
Female	2	0.7	nc	(nc-nc)						
<u>Leukemia</u>					<u>Thyroid</u>					
Male	9	4.8	187.6	(85.6-356.1)	Male	2	1.7	nc	(nc-nc)	
Female	4	4.1	nc	(nc-nc)	Female	8	5.6	143.2	(61.6-282.1)	
Liver and Intrah	nepatic I		<u>s</u>		Uteri Corpus and I	Uterus, N	<u>IOS</u>			
Male	2	3.1	nc	(nc-nc)						
Female	1	1.1	nc	(nc-nc)	Female	15	12.5	120.4	(67.3-198.6)	
Lung and Bron					All Sites / Types					
Male	26	28.7	90.4	(59.1-132.5)	Male	259	206.7	125.3	(110.5-141.6)	
Female	29	25.7	113.0	(75.7-162.4)	Female	206	197.8	104.1	(90.4-119.4)	

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

East BridgewaterObserved and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	Obs O	Exp	SIR	ed Case Courts, v <u>95% CI</u>	viin Standardized inclue	Obs	s, 1999-200 <u>Exp</u>	ง <u>SIR</u>	95% CI
Bladder, Urinar		LVA	<u> 5111</u>	<u>7370 01</u>	Melanoma of Skin	<u>OD3</u>	LXP	<u>Jiik</u>	<u>7370 OI</u>
Male	1 7	11.0	63.4	(25.4-130.6)	Male	7	6.6	105.8	(42.4-217.9)
Female	2	4.0	nc	(nc-nc)	Female	8		142.6	(61.4-280.9)
Brain and Othe				(,	Multiple Myeloma				(****
Male	1	2.5	nc nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
Female	2	2.1	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
<u>Breast</u>				, ,	Non-Hodgkin Lym	phoma			, ,
Male	0	0.4	nc	(nc-nc)	Male	4	6.2	nc	(nc-nc)
Female	58	46.6	124.3	(94.4-160.7)	Female	6	5.4	110.4	(40.3-240.2)
Cervix Uteri					Oral Cavity & Phar	ynx			
					Male	8	4.8	167.7	(72.2-330.5)
Female	3	2.3	nc	(nc-nc)	Female	3	2.2	nc	(nc-nc)
Colon / Rectum	1				<u>Ovary</u>				
Male	23	17.2	134.0	(84.9-201.1)					
Female	20	16.2	123.2	(75.2-190.3)	Female	6	4.9	123.7	(45.2-269.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	2.9	nc	(nc-nc)	Male	1	3.3	nc	(nc-nc)
Female	0	8.0	nc	(nc-nc)	Female	5	3.4	147.2	(47.4-343.6)
<u>Hodgkin Lympl</u>	<u>noma</u>				<u>Prostate</u>				
Male	1	1.1	nc	(nc-nc)	Male	57	47.3	120.6	(91.4-156.3)
Female	2	0.9	nc	(nc-nc)					
Kidney & Rena	l Pelvis				<u>Stomach</u>				
Male	3	5.0	nc	(nc-nc)	Male	1	2.9	nc	(nc-nc)
Female	4	3.1	nc	(nc-nc)	Female	2	1.7	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	2	2.1	nc	(nc-nc)	Male	3	2.1	nc	(nc-nc)
Female	3	0.6	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	1	3.8	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	2	3.1	nc	(nc-nc)	Female	6		122.4	(44.7-266.4)
<u>Liver and Intrahepatic Bile Ducts</u>					Uteri Corpus and L	<u>Jterus, NC</u>	<u>)S</u>		
Male	1	2.3	nc	(nc-nc)					
Female	. 1	8.0	nc	(nc-nc)	Female	9	9.4	95.9	(43.8-182.1)
Lung and Bron		01./	1040	(00.0.100.0)	All Sites / Types	150	45/ 4	101 ((0 / E 110 7)
Male	29	21.6	134.3	(89.9-192.9)	Male	159	156.4	101.6	(86.5-118.7)
Female	14	19.4	72.3	(39.5-121.3)	Female	169	149.3	113.2	(96.7-131.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

East Brookfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	Obs O	Exp	SIR	ed Case Counts, v <u>95% CI</u>	vitri Standardized incident	Obs	Exp	ง <u>SIR</u>	95% CI
Bladder, Urinar		ЕХР	SIK	93 /6 CI	Melanoma of Skin	<u>003</u>	Ехр	<u> SIK</u>	73 /0 CI
Male	y 2	2.4	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
Brain and Othe				(110-110)	Multiple Myeloma	U	1.0	TIC	(116-116)
Male	0	0.5	_	(nc-nc)	Male Male	0	0.4	nc	(nc nc)
Female	0	0.3	nc		Female	0	0.4	nc	(nc-nc)
Breast	U	0.4	nc	(nc-nc)	Non-Hodgkin Lymph		0.3	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	Male	1	1.3	nc	(nc nc)
Female	10	8.4	nc 119.6	(110-110)	Female	2	1.0	nc	(nc-nc)
	10	0.4	119.0	(37.2-219.9)			1.0	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Phary		0.0		(20, 20)
Famala	0	0.4		(20, 20)	Male	0	0.9	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Colon / Rectum	-	0.7		/	<u>Ovary</u>				
Male	1	3.7	nc	(nc-nc)	- 1	4	0.0		/ \
Female	3	3.1	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.6	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Hodgkin Lymph	<u>noma</u>				<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	9	10.0	90.4	(41.3-171.7)
Female	0	0.2	nc	(nc-nc)					
Kidney & Renal	<u>Pelvis</u>				<u>Stomach</u>				
Male	2	1.0	nc	(nc-nc)	Male	3	0.6	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	1	8.0	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
Liver and Intrah	nepatic E	Bile Ducts	<u> </u>		Uteri Corpus and Ut	erus, NOS	<u> </u>		
Male	0	0.5	nc	(nc-nc)					
Female	0	0.2	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
Lung and Brone	<u>chus</u>				All Sites / Types				
Male	8	4.7	171.9	(74.0-338.8)	Male	33	32.8	100.7	(69.3-141.5)
Female	4	3.7	nc	(nc-nc)	Female	27	27.4	98.4	(64.8-143.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

East Longmeadow
Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

			•		with Standardized Incider				050/ 01
Dioddon Ileinon	<u>Obs</u>	<u>Ехр</u>	SIR	<u>95% CI</u>	Malanama of Ckin	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
Bladder, Urinar		10.0	04.0	(E(2.1E0.0)	Melanoma of Skin		0.5	1577	(00.0.0/0.1)
Male	18	19.0	94.9	(56.2-150.0)	Male	15	9.5	157.7	(88.2-260.1)
Female	8 • Namus	7.3	109.9	(47.3-216.7)	Female	7	7.7	91.1	(36.5-187.7)
Brain and Other Nervous System					Multiple Myeloma	4	0.7		, ,
Male	3	3.2	nc	(nc-nc)	Male	1	2.7	nc	(nc-nc)
Female	4	3.0	nc	(nc-nc)	Female	2	2.4	nc	(nc-nc)
<u>Breast</u>				, ,	Non-Hodgkin Lym				(=0.0.010.0)
Male	0	0.6	nc	(nc-nc)	Male	11		119.0	(59.3-213.0)
Female	88	69.2	127.2	(102.0-156.7)	Female	13	9.1	142.5	(75.8-243.8)
Cervix Uteri					Oral Cavity & Phar				
					Male	3	6.7	nc	(nc-nc)
Female	4	2.8	nc	(nc-nc)	Female	5	3.5	140.9	(45.4-328.9)
Colon / Rectum	=				<u>Ovary</u>				
Male	14	28.4	49.3	(26.9-82.8)					
Female	23	30.4	75.7	(48.0-113.6)	Female	7	7.4	94.5	(37.9-194.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	4.6	nc	(nc-nc)	Male	5	5.4	93.4	(30.1-218.0)
Female	1	1.4	nc	(nc-nc)	Female	6	6.4	93.2	(34.0-202.9)
Hodgkin Lymph	<u>noma</u>				<u>Prostate</u>				
Male	3	1.2	nc	(nc-nc)	Male	73	74.6	97.8	(76.7-123.0)
Female	2	1.1	nc	(nc-nc)					
Kidney & Renal	<u>Pelvis</u>				<u>Stomach</u>				
Male	8	7.5	106.7	(46.0-210.3)	Male	6	4.8	126.1	(46.0-274.4)
Female	2	5.1	nc	(nc-nc)	Female	3	3.2	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	5	3.2	157.2	(50.7-366.9)	Male	2	2.0	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	3	5.7	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
Female	5	5.1	98.2	(31.7-229.3)	Female	3	5.6	nc	(nc-nc)
Liver and Intrah	nepatic E	Bile Duc	<u>:ts</u>		Uteri Corpus and I	Uterus, N	<u>os</u>		
Male	2	3.5	nc	(nc-nc)					
Female	4	1.4	nc	(nc-nc)	Female	12	13.9	86.4	(44.6-150.9)
Lung and Brone	<u>chus</u>				All Sites / Types				
Male	27	35.8	75.4	(49.6-109.6)	Male	215	245.8	87.5	(76.2-100.0)
Female	20	33.7	59.4	(36.3-91.8)	Female	246	239.2	102.8	(90.4-116.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

EasthamObserved and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

			•		with Standardized Incide				050/ 01
DI 11 11:	<u>Obs</u>	<u>Ехр</u>	SIR	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
Bladder, Urinar	-	11.0	107.0	// O F 040 F)	Melanoma of Skin	0	F 0	101.0	(00.0.045.1)
Male	14	11.0	127.3	(69.5-213.5)	Male	9	5.0	181.8	(82.9-345.1)
Female	5	3.3	152.4	(49.1-355.6)	Female	6	3.4	179.0	(65.4-389.6)
Brain and Other Nervous System					Multiple Myeloma				
Male	3	1.6	nc	(nc-nc)	Male	6	1.5	393.6	(143.7-856.8)
Female	2	1.3	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<u>Breast</u>					Non-Hodgkin Lym	<u>phoma</u>			
Male	0	0.3	nc	(nc-nc)	Male	4	4.9	nc	(nc-nc)
Female	38	31.2	121.7	(86.1-167.1)	Female	3	4.1	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Phar	<u>ynx</u>			
					Male	3	3.5	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	3	1.6	nc	(nc-nc)
Colon / Rectum	<u>1</u>				<u>Ovary</u>				
Male	17	16.1	105.3	(61.3-168.6)					
Female	20	13.0	153.8	(93.9-237.6)	Female	2	3.3	nc	(nc-nc)
Esophagus					<u>Pancreas</u>				
Male	3	2.6	nc	(nc-nc)	Male	3	3.0	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	2	2.8	nc	(nc-nc)
Hodgkin Lympl	<u>homa</u>				<u>Prostate</u>				
Male	0	0.5	nc	(nc-nc)	Male	64	42.5	150.6	(115.9-192.3)
Female	0	0.4	nc	(nc-nc)					
Kidney & Rena	<u>I Pelvis</u>				<u>Stomach</u>				
Male	2	4.0	nc	(nc-nc)	Male	1	2.7	nc	(nc-nc)
Female	4	2.3	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	1.8	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	3	3.0	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	4	2.1	nc	(nc-nc)	Female	3	2.3	nc	(nc-nc)
Liver and Intral	hepatic E	Bile Duct	<u>is</u>		Uteri Corpus and L	Jterus, N	<u> 10S</u>		
Male	1	1.8	nc	(nc-nc)					
Female	0	0.6	nc	(nc-nc)	Female	9	6.6	136.7	(62.4-259.5)
Lung and Bron	<u>chus</u>				All Sites / Types				
Male	15	20.7	72.5	(40.6-119.6)	Male	159	137.2	115.9	(98.6-135.4)
Female	9	16.2	55.7	(25.4-105.7)	Female	118	107.0	110.3	(91.3-132.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

EasthamptonObserved and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

			•		with Standardized Incide				050/ 01
Dladdor Hriz	<u>Obs</u>	<u>Ехр</u>	<u>SIR</u>	<u>95% CI</u>	Molonoma of Clif-	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
Bladder, Urinary	_	17.1	105.0	((2.2.1/5.0)	Melanoma of Skin		0.4	04.0	(2/ 5 1/7 2)
Male	18	17.1	105.0	(62.2-165.9)	Male	8	9.4	84.8	(36.5-167.2)
Female	7	6.5	108.1	(43.3-222.8)	Female	7	7.9	88.2	(35.3-181.8)
Brain and Other		-			<u>Multiple Myeloma</u>				
Male	3	3.3	nc	(nc-nc)	Male	3	2.5	nc	(nc-nc)
Female	6	3.0	201.2	(73.5-438.0)	Female	1	2.1	nc	(nc-nc)
<u>Breast</u>					Non-Hodgkin Lym	<u>phoma</u>			
Male	0	0.5	nc	(nc-nc)	Male	11		122.4	(61.0-219.0)
Female	73	67.5	108.2	(84.8-136.0)	Female	9	8.5	105.7	(48.2-200.6)
Cervix Uteri					Oral Cavity & Pha	rynx			
					Male	10	6.5	152.9	(73.2-281.1)
Female	1	3.0	nc	(nc-nc)	Female	3	3.4	nc	(nc-nc)
Colon / Rectum					<u>Ovary</u>				
Male	31	26.1	118.8	(80.7-168.6)					
Female	30	27.0	111.2	(75.0-158.7)	Female	5	7.1	70.0	(22.6-163.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	4.2	142.2	(51.9-309.4)	Male	10	4.9	203.8	(97.6-374.8)
Female	0	1.3	nc	(nc-nc)	Female	7	5.7	123.1	(49.3-253.6)
Hodgkin Lymph	<u>ioma</u>				<u>Prostate</u>				
Male	3	1.5	nc	(nc-nc)	Male	55	66.5	82.7	(62.3-107.7)
Female	1	1.3	nc	(nc-nc)					
Kidney & Renal	<u>Pelvis</u>				<u>Stomach</u>				
Male	8	7.1	113.0	(48.6-222.6)	Male	4	4.4	nc	(nc-nc)
Female	3	4.8	nc	(nc-nc)	Female	0	2.8	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	2	2.9	nc	(nc-nc)	Male	1	2.6	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	6	5.4	110.9	(40.5-241.3)	Male	0	1.9	nc	(nc-nc)
Female	3	4.7	nc	(nc-nc)	Female	4	6.4	nc	(nc-nc)
Liver and Intrah	epatic E	Bile Duct	<u>s</u>		Uteri Corpus and	Uterus, N	<u>os</u>		
Male	3	3.4	nc	(nc-nc)					
Female	1	1.3	nc	(nc-nc)	Female	6	13.4	44.8	(16.3-97.4)
Lung and Brond	<u>chus</u>				All Sites / Types				
Male	39	32.3	120.7	(85.8-165.0)	Male	232	227.2	102.1	(89.4-116.1)
Female	21	30.8	68.2	(42.2-104.2)	Female	208	226.3	91.9	(79.9-105.3)
				•					•

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

EastonObserved and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

			•		with Standardized Incide				050/ 01
Diaddan Halaan	<u>Obs</u>	<u>Ехр</u>	<u>SIR</u>	<u>95% CI</u>	Malanana af Chin	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
Bladder, Urinar		10 /	110.0	// 0 0 170 F)	Melanoma of Skin	=	11.0	0044	(100 4 00 (0)
Male	21	18.6	112.8	(69.8-172.5)	Male	23	11.3	204.1	(129.4-306.3)
Female	6	6.4	94.5	(34.5-205.6)	Female	6	9.4	63.7	(23.3-138.7)
Brain and Othe		_			Multiple Myeloma				
Male	2	4.2	nc	(nc-nc)	Male	3	2.8	nc	(nc-nc)
Female	3	3.5	nc	(nc-nc)	Female	0	2.1	nc	(nc-nc)
<u>Breast</u>					Non-Hodgkin Lym	<u>phoma</u>			
Male	0	0.6	nc	(nc-nc)	Male	13		123.4	(65.6-211.0)
Female	99	78.2	126.7	(102.9-154.2)	Female	4	8.9	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pha	<u>rynx</u>			
					Male	7	8.3	84.4	(33.8-174.0)
Female	10	3.8	265.6	(127.1-488.4)	Female	3	3.7	nc	(nc-nc)
Colon / Rectum	<u>1</u>				<u>Ovary</u>				
Male	24	29.1	82.6	(52.9-122.9)					
Female	27	25.8	104.7	(69.0-152.3)	Female	4	8.1	nc	(nc-nc)
Esophagus					<u>Pancreas</u>				
Male	7	5.0	140.0	(56.1-288.5)	Male	5	5.5	90.3	(29.1-210.7)
Female	1	1.3	nc	(nc-nc)	Female	6	5.4	111.6	(40.8-242.9)
Hodgkin Lymph	<u>noma</u>				<u>Prostate</u>				
Male	3	2.0	nc	(nc-nc)	Male	89	81.8	108.8	(87.4-133.9)
Female	3	1.7	nc	(nc-nc)					
Kidney & Rena	l Pelvis				<u>Stomach</u>				
Male	9	8.6	104.7	(47.8-198.8)	Male	4	4.8	nc	(nc-nc)
Female	2	5.1	nc	(nc-nc)	Female	2	2.7	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	1	3.6	nc	(nc-nc)	Male	3	3.5	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	5	6.3	78.8	(25.4-183.9)	Male	3	2.5	nc	(nc-nc)
Female	5	5.0	99.5	(32.1-232.1)	Female	7	8.4	83.5	(33.5-172.1)
Liver and Intral	nepatic	Bile Duc	<u>cts</u>		Uteri Corpus and	Uterus, N	<u>os</u>		
Male	3	4.1	nc	(nc-nc)					
Female	2	1.3	nc	(nc-nc)	Female	10	15.8	63.4	(30.4-116.7)
Lung and Bron	chus				All Sites / Types				
Male	26	36.6	71.0	(46.4-104.1)	Male	257	267.1	96.2	(84.8-108.7)
Female	28	31.5	88.8	(59.0-128.3)	Female	245	245.9	99.6	(87.5-112.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Edgartown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003 95% CI <u>Obs</u> <u>Exp</u> SIR <u>Obs</u> **Exp** <u>SIR</u> 95% CI Bladder, Urinary Melanoma of Skin Male 3 4.0 nc (nc-nc) Male 0 2.4 nc (nc-nc) 2 Female 1.4 nc (nc-nc) Female 3 1.8 (nc-nc) nc **Brain and Other Nervous System** Multiple Myeloma 8.0 Male Male 1 nc (nc-nc) 1 0.6 nc (nc-nc) 0 0.7 0 Female nc (nc-nc) Female 0.4 nc (nc-nc) Non-Hodgkin Lymphoma **Breast** Male 0 0.1 nc (nc-nc) Male 2.2 nc (nc-nc) Female 10 15.7 63.8 (30.5-117.4)Female 3 1.8 (nc-nc) nc Cervix Uteri Oral Cavity & Pharynx Male 1 1.8 (nc-nc) nc Female 1 8.0 (nc-nc) 1 0.7 nc (nc-nc) Female nc Colon / Rectum Ovary Male 4 6.3 (nc-nc) nc Female 10 5.4 183.7 (88.0-337.9) Female 4 1.6 nc (nc-nc) **Pancreas Esophagus** Male 2 1.1 nc (nc-nc) Male 4 1.2 nc (nc-nc) Female 1 0.3 nc (nc-nc) Female 4 1.2 nc (nc-nc) Hodgkin Lymphoma **Prostate** Male 0 0.3 Male 18 102.3 (60.6-161.8)nc (nc-nc) 17.6 Female 0.3 1 nc (nc-nc) Kidney & Renal Pelvis Stomach Male 2 1.8 Male 0 1.0 (nc-nc) nc (nc-nc) nc Female 1 1.1 Female 0 nc (nc-nc) 0.6 nc (nc-nc) **Larynx Testis** 1 0 Male 8.0 nc (nc-nc) Male 0.6 nc (nc-nc) Female 1 0.2 nc (nc-nc) Leukemia **Thyroid**

• Obs = observed case count; Exp = expected case count;

1.3

1.0

0.9

0.3

8.0

6.8

0

1

0

10

5

Liver and Intrahepatic Bile Ducts

nc

nc

nc

nc

125.5

73.9

Male

Male

Female

Lung and Bronchus

Male

Female

Female

- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

(nc-nc)

(nc-nc)

(nc-nc)

(nc-nc)

(60.1-230.9)

(23.8-172.5)

- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

0

1

4

55

56

0.5

1.5

3.2

57.0

nc

nc

nc

96.5

50.0 112.0

(nc-nc)

(nc-nc)

(nc-nc)

(72.7-125.7)

(84.6-145.5)

Male

Uteri Corpus and Uterus, NOS

Female

Female

Male

Female

All Sites / Types

Egremont Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003									
	<u>Obs</u>	Ехр	SIR	95% CI	.,	<u>Obs</u>	Ехр	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	1	2.4	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
Brain and Other N	ervous Sy	<u>/stem</u>			Multiple Myeloma				
Male	0	0.4	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					Non-Hodgkin Lymph	<u>oma</u>			
Male	0	0.1	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	4	7.4	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharyn	<u>x</u>			
					Male	1	0.8	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Colon / Rectum					<u>Ovary</u>				
Male	2	3.6	nc	(nc-nc)					
Female	2	2.7	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.6	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
Hodgkin Lymphor	<u>na</u>				<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	4	9.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)					
Kidney & Renal Pe	<u>elvis</u>				<u>Stomach</u>				
Male	0	0.9	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	0	0.7	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
Liver and Intrahep	atic Bile [<u>Oucts</u>			Uteri Corpus and Ute	rus, NOS			
Male	0	0.4	nc	(nc-nc)					
Female	0	0.1	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
Lung and Bronchu	<u>us</u>				All Sites / Types				
Male	2	4.5	nc	(nc-nc)	Male	13	30.8	42.3	(22.5-72.3)
Female	2	3.4	nc	(nc-nc)	Female	17	23.9	71.1	(41.4-113.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Erving

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003									
	<u>Obs</u>	<u>Exp</u>	SIR	95% CI		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
Bladder, Urinary					Melanoma of Skin				
Male	4	1.8	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Brain and Other N	ervous Sy	<u>/stem</u>			Multiple Myeloma				
Male	0	0.3	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					Non-Hodgkin Lympho	<u>oma</u>			
Male	0	0.1	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	4	6.1	nc	(nc-nc)	Female	2	0.7	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharyn	<u>x</u>			
					Male	0	0.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
Colon / Rectum					<u>Ovary</u>				
Male	0	2.7	nc	(nc-nc)					
Female	2	2.3	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Hodgkin Lymphon	<u>na</u>				<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	6	7.2	82.9	(30.3-180.5)
Female	0	0.1	nc	(nc-nc)					
Kidney & Renal Pe	<u>elvis</u>				<u>Stomach</u>				
Male	0	0.7	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	2	0.6	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Liver and Intrahep	atic Bile [<u>Ducts</u>			Uteri Corpus and Ute	rus, NOS			
Male	0	0.3	nc	(nc-nc)					
Female	0	0.1	nc	(nc-nc)	Female	3	1.2	nc	(nc-nc)
Lung and Bronchu	<u>IS</u>				All Sites / Types				
Male	3	3.4	nc	(nc-nc)	Male	20		83.6	(51.1-129.2)
Female	3	2.7	nc	(nc-nc)	Female	18	20.1	89.7	(53.1-141.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

ESSEXObserved and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

0			-		ith Standardized Incidend				OEW CI
	<u>bs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>	Melanoma of Skin	<u>Obs</u>	<u>Ехр</u>	<u>SIR</u>	<u>95% CI</u>
Bladder, Urinary Male	Е	2.7	125 /	(42 7 21/ 1)	Male	4	2.1	no	(no no)
	5	3.7	135.4	(43.7-316.1)	Female	4	2.1	nc	(nc-nc)
Female	0	1.2	nc •••••	(nc-nc)		3	1.6	nc	(nc-nc)
Brain and Other I		-		()	Multiple Myeloma	1	٥٦		(
Male	0	0.7	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	6	0.6	1028.3	(375.5-2238.3)	Female	0	0.4	nc	(nc-nc)
<u>Breast</u>				, ,	Non-Hodgkin Lymp				, ,
Male	0	0.1	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
	19	13.4	141.8	(85.3-221.5)	Female	1	1.6	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Phary				
	_			, ,	Male .	1	1.5	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Colon / Rectum					<u>Ovary</u>				
Male	4	5.7	nc	(nc-nc)					
Female	6	4.9	122.2	(44.6-266.0)	Female	0	1.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.9	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	3	1.0	nc	(nc-nc)
<u>Hodgkin Lympho</u>	<u>ma</u>				<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	20	15.4	129.9	(79.3-200.6)
Female	0	0.2	nc	(nc-nc)					
Kidney & Renal P	Pelvis	<u>S</u>			<u>Stomach</u>				
Male	0	1.6	nc	(nc-nc)	Male	2	0.9	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	2	0.5	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	1	0.7	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	1	1.2	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
Liver and Intrahe	patio	: Bile Du	<u>icts</u>		Uteri Corpus and U	terus, NO	<u>S</u>		
Male	0	8.0	nc	(nc-nc)					
Female	0	0.2	nc	(nc-nc)	Female	1	2.7	nc	(nc-nc)
Lung and Bronch	<u>ius</u>				All Sites / Types				
Male	5	7.2	69.3	(22.3-161.6)	Male	52	50.5	102.9	(76.8-135.0)
Female	13	5.9	221.1	(117.6-378.2)	Female	58	43.5	133.4	(101.3-172.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

EverettObserved and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

			•		with Standardized Incide				
	<u>Obs</u>	<u>Ехр</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Ехр</u>	SIR	<u>95% CI</u>
Bladder, Urina	<u>ary</u>				Melanoma of Skin				
Male	49	39.6	123.8	(91.6-163.7)	Male	11	20.9	52.6	(26.2-94.1)
Female	11	15.7	70.1	(34.9-125.4)	Female	15	18.6	80.6	(45.1-132.9)
Brain and Oth	er Nervo	ous Syste	<u>m</u>		Multiple Myeloma				
Male	16	7.4	215.7	(123.2-350.3)	Male	6	5.7	105.9	(38.7-230.6)
Female	3	7.1	nc	(nc-nc)	Female	1	5.1	nc	(nc-nc)
<u>Breast</u>					Non-Hodgkin Lym	<u>phoma</u>			
Male	1	1.2	nc	(nc-nc)	Male	21	20.2	103.9	(64.3-158.8)
Female	133	155.2	85.7	(71.7-101.6)	Female	23	20.3	113.1	(71.7-169.7)
Cervix Uteri					Oral Cavity & Phar	<u>ynx</u>			
					Male	18	14.1	127.2	(75.4-201.1)
Female	5	7.0	71.7	(23.1-167.2)	Female	12	8.0	150.9	(77.9-263.7)
Colon / Rectu	<u>m</u>				<u>Ovary</u>				
Male	80	59.4	134.8	(106.8-167.7)					
Female	72	64.7	111.3	(87.1-140.1)	Female	21	16.6	126.2	(78.1-192.9)
Esophagus					<u>Pancreas</u>				
Male	12	9.6	125.3	(64.7-218.9)	Male	13	11.2	116.5	(62.0-199.3)
Female	3	3.1	nc	(nc-nc)	Female	22	13.7	160.3	(100.4-242.7)
Hodgkin Lym	<u>ohoma</u>				<u>Prostate</u>				
Male	2	3.4	nc	(nc-nc)	Male	142	155.7	91.2	(76.8-107.5)
Female	4	3.1	nc	(nc-nc)					
Kidney & Ren	al Pelvis	<u>i</u>			Stomach Stomach				
Male	15	15.8	94.9	(53.1-156.6)	Male	13	10.0	129.7	(69.0-221.9)
Female	23	11.3	204.0	(129.3-306.1)	Female	10	6.9	145.7	(69.7-267.9)
<u>Larynx</u>					<u>Testis</u>				
Male	6	6.6	90.3	(33.0-196.4)	Male	5	6.5	77.1	(24.8-179.9)
Female	1	2.0	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	13	12.4	104.6	(55.7-178.9)	Male	2	4.3	nc	(nc-nc)
Female	13	11.3	114.7	(61.0-196.1)	Female	18	14.9	120.6	(71.4-190.6)
Liver and Intra	ahepatic	Bile Duc	t <u>s</u>		Uteri Corpus and L	Jterus, N	<u>NOS</u>		
Male	7	7.3	95.8	(38.4-197.4)					
Female	2	3.2	nc	(nc-nc)	Female	22	31.3	70.2	(44.0-106.3)
Lung and Bro	<u>nchus</u>				All Sites / Types				
Male	97	74.7	129.9	(105.4-158.5)	Male	570	521.4	109.3	(100.5-118.7)
Female	99	74.1	133.5	(108.5-162.6)	Female	548	533.7	102.7	(94.3-111.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Fairhaven
Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

			•		with Standardized Incid				050/ 01
Diaddan Halasa	<u>Obs</u>	<u>Ехр</u>	<u>SIR</u>	<u>95% CI</u>	Malanana af Chin	<u>Obs</u>	<u>Exp</u>	SIR	<u>95% CI</u>
Bladder, Urinar		00.0	405.0	(01.0.100.0)	Melanoma of Skin	,	10.0	F 4 0	(00 0 110 5)
Male	30	22.2	135.3	(91.3-193.2)	Male	6	10.9	54.9	(20.0-119.5)
Female	6	8.8	68.1	(24.9-148.3)	Female	9	9.1	99.2	(45.3-188.3)
Brain and Othe		-	<u>m</u>		Multiple Myeloma				
Male	4	3.7	nc	(nc-nc)	Male	3	3.1	nc	(nc-nc)
Female	4	3.5	nc	(nc-nc)	Female	2	2.9	nc	(nc-nc)
<u>Breast</u>					Non-Hodgkin Lym	<u>phoma</u>			
Male	0	0.7	nc	(nc-nc)	Male	12	10.7	112.3	(58.0-196.2)
Female	81	81.0	100.0	(79.4-124.3)	Female	12	11.0	109.5	(56.5-191.2)
Cervix Uteri					Oral Cavity & Phar	<u>ynx</u>			
					Male	6	7.6	78.9	(28.8-171.7)
Female	2	3.2	nc	(nc-nc)	Female	2	4.2	nc	(nc-nc)
Colon / Rectum	<u>1</u>				<u>Ovary</u>				
Male	31	33.0	93.8	(63.8-133.2)					
Female	32	37.1	86.2	(59.0-121.7)	Female	10	8.8	114.2	(54.7-210.0)
Esophagus					<u>Pancreas</u>				
Male	5	5.3	95.1	(30.6-221.9)	Male	1	6.2	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)	Female	9	7.8	114.7	(52.3-217.8)
Hodgkin Lympl	<u>homa</u>				<u>Prostate</u>				
Male	2	1.4	nc	(nc-nc)	Male	109	84.3	129.4	(106.2-156.1)
Female	1	1.3	nc	(nc-nc)					
Kidney & Rena	l Pelvis				<u>Stomach</u>				
Male	13	8.5	152.8	(81.3-261.3)	Male	8	5.6	142.9	(61.5-281.7)
Female	6	6.0	99.6	(36.4-216.8)	Female	3	4.0	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	2	3.6	nc	(nc-nc)	Male	3	2.3	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	7	6.5	107.0	(42.9-220.5)	Male	1	2.0	nc	(nc-nc)
Female	7	6.1	114.6	(45.9-236.1)	Female	5	6.5	77.2	(24.9-180.1)
Liver and Intral	hepatic I	3ile Duct	is.		Uteri Corpus and I	Jterus, N	IOS		
Male	2	3.9	nc	(nc-nc)					
Female	0	1.8	nc	(nc-nc)	Female	14	16.3	85.8	(46.9-144.0)
Lung and Bron	chus				All Sites / Types				
Male	41	41.1	99.7	(71.6-135.3)	Male	303	282.1	107.4	(95.7-120.2)
Female	35	40.2	87.1	(60.6-121.1)	Female	267	285.0	93.7	(82.8-105.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Fall River
Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

Male Male				•		ith Standardized Incid		_		050/ 01
Male Female 102 104.1 98.0 (79.9-119.0) Male Female 15 52.4 28.6 (16.0-47.2) Female Pemale 51 51 44.3 115.2 (85.8-151.5) Female 22 47.0 46.8 (29.3-70.8) Brain and Other Personale 23 18.5 70.5 (37.5-120.6) Male 17 14.8 15.2 (67.1-184.4) Female 23 18.5 70.5 (37.5-120.6) Male 10 14.4 69.4 (33.2-127.7) Breast 3 3.1 nc (nc-nc) Male 44 51.3 85.8 (62.3-115.2) Personale 3 3.1 nc (nc-nc) Male 44 51.3 85.8 (62.3-115.2) Personale 2 16.8 154.7 (101.1-226.7) Female 2 21.3 39.3 (57.3-144.9) Personale 165 155.3 106.3 (90.7-123.8) Female 39	BI II II.	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
Female 22 47.0 46.8 (29.3.708) Brain and Olber Veryevery System Multiple Myelom Male 13 18.4 70.5 (37.5-120.6) Male 17 14.8 11.52 (67.1-184.4) Female 23 18.5 124.4 (78.8-186.7) Female 10 14.8 11.52 (67.1-184.4) Breast Non-Hodgkir Promose Female 3 3.1 nc (nc-nc) Male 44 51.3 85.8 (62.3-115.2) Female 3 3.1 nc (nc-nc) Male 44 51.3 85.8 (62.3-115.2) 70<					(=0.0.110.0)			=		(1 (0 (7 0)
Malle Brian and Other Service Multiple Myester Myester Multiple Myester Myeste										
Male 13 18.4 70.5 (37.5-120.6) Male 17 14.8 15.2 (67.1-184.4) Female 23 18.5 124.4 (78.8-186.7) Female 10 14.4 69.4 (33.2-127.7) Breast Non-Hodgkin Jumps Male 3 3.1 nc (nc-nc) Male 44 51.3 85.8 (62.3-115.2) Female 3 3.1 nc (nc-nc) Male 44 51.3 55.8 (62.3-115.2) Cervix Uteri Male 48 35.7 134.3 (99.0-178.0) Female 26 16.8 154.7 (101.1-226.7) Pemale 20 21.3 39.3 (97.3-144.0) Colon/ Recture Description Openate 2 155.3 106.3 (90.7-123.8) Pemale 3 44.1 88.5 (62.9-121.0) Pemale 3 124.7 212.6					(85.8-151.5)			47.0	46.8	(29.3-70.8)
Female 23 18.5 124.4 (78.8-186.7) Female 10 14.4 69.4 (33.2-127.7) Breast Non-Hodgkin ⊥mm Male 32 3.1 nc (nc-nc) Male 44 51.3 85.8 (62.3-115.2) Female 329 404.0 81.4 (72.9-90.7) Female 54 55.7 97.0 (72.8-126.5) Cervix Uteri Breale 26 16.8 154.7 (101.1-226.7) Female 20 21.3 35.3 (99.0-178.0) Female 26 16.5 155.3 106.3 (907-123.8) Female 20 44.1 88.5 (52.9-121.0) Permale 165 185.0 186.9 (75.9-103.6) Female 39 44.1 88.5 (62.9-121.0) Permale 3 24.7 21.1 (82.0-173.6) Male 34 29.2 14.4 (80.6-162.7) (80.6-162.7) Permale			-			· · · · · · · · ·				
Breast Jame 33 3.1 nc (nc-nc) Male 44 51.3 85.8 (62.3-115.2) Female 329 404.0 81.4 (72.9-90.7) Female 54 55.7 97.0 (72.8-126.5) Cervix Uteri	Male				(37.5-120.6)	Male			115.2	(67.1-184.4)
Male 3 3.1 nc (nc-nc) Male 44 51.3 85.8 (62.3-115.2) Female 329 404.0 81.4 (72.9-90.7) Female 54 55.7 97.0 (72.8-126.5) Cervix Uteri The strict of the strict	Female	23	18.5	124.4	(78.8-186.7)	Female	10	14.4	69.4	(33.2-127.7)
Female 329 404.0 81.4 (72.9-90.7) Female 54 55.7 97.0 (72.8-126.8) Cervix Uter) Cervix Uter Female 48 35.7 13.43 (99.0-178.0) 6 76.0 76.0 20 21.3 93.0 (57.3-144.9) 76.0 76.0 20 21.3 93.0 (57.3-144.9) 76.0 76.0 76.0 20 21.3 93.0 (57.3-144.9) 76.0 <td><u>Breast</u></td> <td></td> <td></td> <td></td> <td></td> <td>Non-Hodgkin Ly</td> <td><u>mphoma</u></td> <td></td> <td></td> <td></td>	<u>Breast</u>					Non-Hodgkin Ly	<u>mphoma</u>			
Cervix Uteri Coral Cavity & Premate 48 35.7 13.43 (90.0-178.0) Female 26 16.8 154.7 (101.1-226.7) Female 20 21.3 93.8 (57.3-144.9) Colon / Rectus Male 165 155.3 106.3 (90.7-123.8) Female 39 44.1 80.5 (62.0-120.0) Pactreas Male 30 24.7 121.6 (82.0-173.6) Male 34 29.2 116.4 (80.6-162.7) Female 30 24.7 121.6 (82.0-173.6) Male 34 29.2 116.4 (80.6-162.7) Female 30 24.7 121.6 (82.0-173.6) Female 34 29.2 10.4 (80.6-162.7) Female 7 8.8 79.6 (13.1-164.1) Female 32 30.0 (30.1-126.6) 34 30.0 30.1 (80.6-162.7) 40.2 10.2 40.2 10.2 40.2 10.2	Male	3	3.1	nc	(nc-nc)	Male	44	51.3	85.8	(62.3-115.2)
Female 26 16.8 154.7 (101.1-226.7) Female 20 21.3 23.3 (90.0-178.0) Colon / Recture Description of the property	Female	329	404.0	81.4	(72.9-90.7)	Female	54	55.7	97.0	(72.8-126.5)
Female 26 16.8 154.7 (101.1-226.7) Female 20 21.3 93.8 (57.3-144.9) Colon / Recture Male 165 155.3 106.3 (90.7-123.8) Female 39 44.1 88.5 (62.9-121.0) Female 165 185.6 88.9 (75.9-103.6) Female 39 44.1 88.5 (62.9-121.0) Besophagus Pancreas Male 20 24.7 121.6 (82.0-173.6) Male 34 29.2 116.4 (80.6-162.7) Female 7 8.8 79.6 (31.9-164.1) Female 36 39.4 91.5 (64.0-126.6) Postate Female 9 7.9 113.4 (51.7-215.2) Male 324 396.3 81.7 (73.1-91.2) Female 4 40.2 112.0 (81.7-149.9) Male 33 26.3 125.6 (86.4-176.4)	Cervix Uteri					Oral Cavity & Ph	<u>arynx</u>			
Colon / Recture Colon / Recture Colon / Recture Serial (a) 165 155.3 106.3 (90.7-123.8) Female 39 44.1 88.5 (62.9-121.0) Esophagus Pancreas Male 30 24.7 121.6 (82.0-173.6) Male 34 29.2 116.4 (80.6-162.7) Female 7 8.8 79.6 (31.9-164.1) Female 36 39.4 91.5 (64.0-126.0) Hodgkin Lym-brane 7 8.8 79.6 (31.9-164.1) Female 324 396.3 81.7 (64.0-126.0) Hodgkin Lym-brane 7 113.4 (51.7-215.2) Male 324 396.3 81.7 (64.0-126.0) Hodgkin Lym-brane 7 113.4 (51.7-215.2) Male 324 396.3 81.7 (73.1-91.2) Hodgkin Lym-brane 9 7 113.4 (51.7-215.2) Stomach 12.5 12.6 (86.4-176.4) <						Male	48	35.7	134.3	(99.0-178.0)
Male Female 165 155.3 106.3 (90.7-123.8) Female 39 44.1 88.5 (62.9-121.0) Esophagus Pancreas Male 30 24.7 121.6 (82.0-173.6) Male 34 29.2 116.4 (80.6-162.7) Female 30 24.7 121.6 (82.0-173.6) Male 34 29.2 116.4 (80.6-162.7) Female 30 24.7 121.6 (82.0-173.6) Male 34 29.2 116.4 (80.6-162.7) Hodgkin Lym-y	Female	26	16.8	154.7	(101.1-226.7)	Female	20	21.3	93.8	(57.3-144.9)
Female 165 185.6 88.9 (75.9-103.6) Female 39 44.1 88.5 (62.9-121.0) Esophagus Pancreas Male 30 24.7 121.6 (82.0-173.6) Male 34 29.2 116.4 (80.6-162.7) Female 7 8.8 79.6 (31.9-164.1) Female 36 39.4 91.5 (64.0-126.6) Hodgkin Lym>rus Female 9 7.9 113.4 (51.7-215.2) Male 324 396.3 81.7 (73.1-91.2) Female 6 7.6 78.7 (28.7-171.3) Male 324 396.3 81.7 (73.1-91.2) Kidney & Renter Pelvis Stomach Stomach Kidney & Renter Pelvis Stomach Early 18 45 40.2 112.0 (81.7-149.9) Male 33 26.3 125.6 (86.4-176.4) Female 26 17.0	Colon / Rectur	<u>m</u>				<u>Ovary</u>				
Esophagus Pancreas Male 30 24.7 121.6 (82.0-173.6) Male 34 29.2 116.4 (80.6-162.7) Female 7 8.8 79.6 (31.9-164.1) Female 36 39.4 91.5 (64.0-126.6) Hodgkin Lymby Female 9 7.9 113.4 (51.7-215.2) Male 324 396.3 81.7 (73.1-91.2) Female 9 7.9 113.4 (51.7-215.2) Male 324 396.3 81.7 (73.1-91.2) Female 9 7.9 113.4 (51.7-215.2) Male 324 396.3 81.7 (73.1-91.2) Kidney & Renale 9 7.9 112.4 (81.7-17.13) 125.0 86.4-176.4 48.2 48.2 49.2 125.6 (86.4-176.4) 49.2 125.0 (86.4-176.4) 49.2 125.0 (86.4-176.4) 49.2 125.0 (86.4-176.4) 49.2 125.0	Male	165	155.3	106.3	(90.7-123.8)					
Male 30 24.7 121.6 (82.0-173.6) Male 34 29.2 116.4 (80.6-162.7) Female 7 8.8 79.6 (31.9-164.1) Female 36 39.4 91.5 (64.0-126.6) Hodgkin Lymy-residual Prostate Male 9 7.9 113.4 (51.7-215.2) Male 324 396.3 81.7 (73.1-91.2) Female 6 7.6 78.7 (28.7-171.3) 25.0 32.4 396.3 81.7 (73.1-91.2) Kidney & Renzle Pulvis Stomach Male 45 40.2 112.0 (81.7-149.9) Male 33 26.3 125.6 (86.4-176.4) Female 32 30.5 105.0 (71.8-148.2) Female 29 19.9 145.6 (97.5-209.1) Larynx Testis Testis Leukemia 13 31.9 (99.9-224.1) Male 4 10.0 nc (nc-nc) <th< td=""><td>Female</td><td>165</td><td>185.6</td><td>88.9</td><td>(75.9-103.6)</td><td>Female</td><td>39</td><td>44.1</td><td>88.5</td><td>(62.9-121.0)</td></th<>	Female	165	185.6	88.9	(75.9-103.6)	Female	39	44.1	88.5	(62.9-121.0)
Female 7 8.8 79.6 (31.9-164.1) Female 36 39.4 91.5 (64.0-126.6) Hodgkin Lymptor Male 9 7.9 113.4 (51.7-215.2) Male 324 396.3 81.7 (73.1-91.2) Female 6 7.6 78.7 (28.7-171.3) Stomach Stomach Stomach Kidney & Renul Pulvis Stomach Male 45 40.2 112.0 (81.7-149.9) Male 33 26.3 125.6 (86.4-176.4) Female 32 30.5 105.0 (71.8-148.2) Female 29 19.9 145.6 (97.5-209.1) Larynx Testis Male 26 17.0 153.0 (99.9-224.1) Male 4 13.8 nc (nc-nc) Female 12 5.2 29.2 (118.3-400.4) 10.0 nc (nc-nc) Female 28 31.5 89.0	Esophagus					<u>Pancreas</u>				
Hodgkin Lymbys Prostate Male 9 7.9 113.4 (51.7-215.2) Male 324 396.3 81.7 (73.1-91.2) Female 6 7.6 78.7 (28.7-171.3) Stomach Female Female Female Female Female Female Stomach Female Stomach Female Stomach Female Prostate Stomach Female Stomach Stomach Female Stomach St	Male	30	24.7	121.6	(82.0-173.6)	Male	34	29.2	116.4	(80.6-162.7)
Male 9 7.9 113.4 (51.7-215.2) Male 324 396.3 81.7 (73.1-91.2) Female 6 7.6 78.7 (28.7-171.3) Stomach Kidney & Renal Pelvis Stomach Male 45 40.2 112.0 (81.7-149.9) Male 33 26.3 125.6 (86.4-176.4) Female 32 30.5 105.0 (71.8-148.2) Female 29 19.9 145.6 (97.5-209.1) Larynx Testis Male 26 17.0 153.0 (99.9-224.1) Male 4 13.8 nc (nc-nc) Female 12 5.2 229.2 (118.3-400.4) Thyroid Thyroid nc (nc-nc) Female 41 31.9 128.4 (92.1-174.2) Male 4 10.0 nc (nc-nc) Female 28 31.5 89.0 (59.1-128.6) Female 34	Female	7	8.8	79.6	(31.9-164.1)	Female	36	39.4	91.5	(64.0-126.6)
Female 6 7.6 78.7 (28.7-171.3) Stomach Kidney & Renal Pelvis Stomach Male 45 40.2 112.0 (81.7-149.9) Male 33 26.3 125.6 (86.4-176.4) Female 32 30.5 105.0 (71.8-148.2) Female 29 19.9 145.6 (97.5-209.1) Larynx Testis Male 26 17.0 153.0 (99.9-224.1) Male 4 13.8 nc (nc-nc) Female 12 5.2 229.2 (118.3-400.4) Thyroid Thyroid Thyroid nc (nc-nc) (nc-nc) Female 41 31.9 128.4 (92.1-174.2) Male 4 10.0 nc (nc-nc) Female 28 31.5 89.0 (59.1-128.6) Female 34 34.8 97.6 (67.6-136.4) 14.0 14.0 14.0 14.0 14.0 14.0	<u>Hodgkin Lymp</u>	<u>ohoma</u>				<u>Prostate</u>				
Kidney & Renale Pelvis Stomach Male 45 40.2 112.0 (81.7-149.9) Male 33 26.3 125.6 (86.4-176.4) Female 32 30.5 105.0 (71.8-148.2) Female 29 19.9 145.6 (97.5-209.1) Larynx Testis Male 26 17.0 153.0 (99.9-224.1) Male 4 13.8 nc (nc-nc) Female 12 5.2 229.2 (118.3-400.4) Thyroid Thyroid Thyroid 1 10.0 nc (nc-nc) Male 41 31.9 128.4 (92.1-174.2) Male 4 10.0 nc (nc-nc) Female 28 31.5 89.0 (59.1-128.6) Female 34 34.8 97.6 (67.6-136.4) Liver and Intra-patic Elle Ducts Uteri Corpus and Uterus, NOS V V V V V V V V V V V V V V V V V V<	Male	9	7.9	113.4	(51.7-215.2)	Male	324	396.3	81.7	(73.1-91.2)
Male 45 40.2 112.0 (81.7-149.9) Male 33 26.3 125.6 (86.4-176.4) Female 32 30.5 105.0 (71.8-148.2) Female 29 19.9 145.6 (97.5-209.1) Larynx Testis Male 26 17.0 153.0 (99.9-224.1) Male 4 13.8 nc (nc-nc) Female 12 5.2 229.2 (118.3-400.4) Thyroid Thyroid Thyroid Na 97.6 (nc-nc) Female 41 31.9 128.4 (92.1-174.2) Male 4 10.0 nc (nc-nc) Female 28 31.5 89.0 (59.1-128.6) Female 34 34.8 97.6 (67.6-136.4) Liver and Intrabepatic Bile Ducts Utteri Corpus and Uterus, NOS Female 26 18.5 140.3 (91.6-205.5) Female 76 81.6 93.1 (73.4-116.5)	Female	6	7.6	78.7	(28.7-171.3)					
Female 32 30.5 105.0 (71.8-148.2) Female 29 19.9 145.6 (97.5-209.1) Larynx Testis Male 26 17.0 153.0 (99.9-224.1) Male 4 13.8 nc (nc-nc) Female 12 5.2 229.2 (118.3-400.4) Thyroid Thyroid v v v √nc-nc) Male 41 31.9 128.4 (92.1-174.2) Male 4 10.0 nc (nc-nc) Female 28 31.5 89.0 (59.1-128.6) Female 34 34.8 97.6 (67.6-136.4) Liver and Intrable 18.5 140.3 (91.6-205.5) Uteri Corpus and Uterus, NOS V </td <td>Kidney & Rena</td> <td>al Pelvis</td> <td></td> <td></td> <td></td> <td><u>Stomach</u></td> <td></td> <td></td> <td></td> <td></td>	Kidney & Rena	al Pelvis				<u>Stomach</u>				
Testis Male 26 17.0 153.0 (99.9-224.1) Male 4 13.8 nc (nc-nc) Female 12 5.2 229.2 (118.3-400.4) Thyroid Thyroid V V Cnc-nc) Male 41 31.9 128.4 (92.1-174.2) Male 4 10.0 nc (nc-nc) Female 28 31.5 89.0 (59.1-128.6) Female 34 34.8 97.6 (67.6-136.4) Liver and Intrabepatic Ble Ducts Uteri Corpus and Uterus, NOS Male 26 18.5 140.3 (91.6-205.5) Female 76 81.6 93.1 (73.4-116.5)	Male	45	40.2	112.0	(81.7-149.9)	Male	33	26.3	125.6	(86.4-176.4)
Male 26 17.0 153.0 (99.9-224.1) Male 4 13.8 nc (nc-nc) Female 12 5.2 229.2 (118.3-400.4) Thyroid Leukemia Thyroid Male 41 31.9 128.4 (92.1-174.2) Male 4 10.0 nc (nc-nc) Female 28 31.5 89.0 (59.1-128.6) Female 34 34.8 97.6 (67.6-136.4) Liver and Intrabepatic Bile Ducts Uteri Corpus and Uterus, NOS Male 26 18.5 140.3 (91.6-205.5) Female 76 81.6 93.1 (73.4-116.5)	Female	32	30.5	105.0	(71.8-148.2)	Female	29	19.9	145.6	(97.5-209.1)
Female 12 5.2 229.2 (118.3-400.4) Leukemia Thyroid Male 41 31.9 128.4 (92.1-174.2) Male 4 10.0 nc (nc-nc) Female 28 31.5 89.0 (59.1-128.6) Female 34 34.8 97.6 (67.6-136.4) Liver and Intrabepatic Bile Ducts Utteri Corpus and Uterus, NOS Male 26 18.5 140.3 (91.6-205.5) Female 76 81.6 93.1 (73.4-116.5)	<u>Larynx</u>					<u>Testis</u>				
Thyroid Male 41 31.9 128.4 (92.1-174.2) Male 4 10.0 nc (nc-nc) Female 28 31.5 89.0 (59.1-128.6) Female 34 34.8 97.6 (67.6-136.4) Liver and Intrabepatic Bile Ducts Uteri Corpus and Uterus, NOS Male 26 18.5 140.3 (91.6-205.5) Female 1 89.9 124.2 (61.9-222.3) Female 76 81.6 93.1 (73.4-116.5)	Male	26	17.0	153.0	(99.9-224.1)	Male	4	13.8	nc	(nc-nc)
Male 41 31.9 128.4 (92.1-174.2) Male 4 10.0 nc (nc-nc) Female 28 31.5 89.0 (59.1-128.6) Female 34 34.8 97.6 (67.6-136.4) Liver and Intrabepatic Full Ducts Uteri Corpus and Uterus, NOS Male 26 18.5 140.3 (91.6-205.5) Female 76 81.6 93.1 (73.4-116.5)	Female	12	5.2	229.2	(118.3-400.4)					
Female 28 31.5 89.0 (59.1-128.6) Female 34 34.8 97.6 (67.6-136.4) Liver and Intrahepatic Bile Ducts Uteri Corpus and Uterus, NOS Male 26 18.5 140.3 (91.6-205.5) Female 76 81.6 93.1 (73.4-116.5)	<u>Leukemia</u>					<u>Thyroid</u>				
Liver and Intrahepatic Bile Ducts Uteri Corpus and Uterus, NOS Male 26 18.5 140.3 (91.6-205.5) Female 11 8.9 124.2 (61.9-222.3) Female 76 81.6 93.1 (73.4-116.5)	Male	41	31.9	128.4	(92.1-174.2)	Male	4	10.0	nc	(nc-nc)
Male 26 18.5 140.3 (91.6-205.5) Female 11 8.9 124.2 (61.9-222.3) Female 76 81.6 93.1 (73.4-116.5)	Female	28	31.5	89.0	(59.1-128.6)	Female	34	34.8	97.6	(67.6-136.4)
Male 26 18.5 140.3 (91.6-205.5) Female 11 8.9 124.2 (61.9-222.3) Female 76 81.6 93.1 (73.4-116.5)	Liver and Intra	hepatic	Bile Duct	<u>s</u>		Uteri Corpus and	l Uterus,	NOS		
		•			(91.6-205.5)	•				
<u>Lung and Bronchus</u> <u>All Sites / Types</u>	Female	11	8.9			Female	76	81.6	93.1	(73.4-116.5)
	Lung and Broi	nchus				All Sites / Types				
Male 269 193.4 139.1 (123.0-156.8) Male 1364 1336.5 102.1 (96.7-107.6)	-		193.4	139.1	(123.0-156.8)		1364	1336.5	102.1	(96.7-107.6)
Female 170 203.5 83.5 (71.5-97.1) Female 1296 1437.3 90.2 (85.3-95.2)										

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Falmouth
Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

			-		with Standardized inclu				OEO/ CI
Bladder, Urina	Obs	<u>Ехр</u>	<u>SIR</u>	<u>95% CI</u>	Melanoma of Skin	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
Male	<u>11 y</u> 65	54.3	119.8	(92.4-152.6)	Male	<u>.</u> 44	25.6	172.2	(125.1-231.1)
Female	21	18.7	112.0	(69.3-171.3)	Female	33		169.8	(125.1-231.1)
Brain and Oth				(09.3-171.3)	Multiple Myeloma		17.4	107.0	(110.9-230.3)
		-	168.5	(02.1.202.0)			7.4	102.2	(100 1 207 E)
Male	14	8.3		(92.1-282.8)	Male	14	7.6	183.3	(100.1-307.5)
Female	9	7.5	120.1	(54.8-228.0)	Female Non-Hodgkin Lym	14	6.1	229.1	(125.1-384.4)
<u>Breast</u>	_	1 /	200.2	(00.2.710.2)		-	25.1	05 /	(/1 2 142 2)
Male	5	1.6	308.2	(99.3-719.2)	Male	24	25.1	95.6	(61.2-142.3)
Female	208	179.5	115.9	(100.7-132.8)	Female	26	23.3	111.6	(72.9-163.5)
Cervix Uteri					Oral Cavity & Pha				(0.4.0.4.0.4.0.)
					Male	10	18.2	55.0	(26.3-101.2)
Female	8	6.9	115.5	(49.7-227.5)	Female	7	9.2	76.1	(30.5-156.7)
Colon / Rectu					<u>Ovary</u>				
Male	85	80.4	105.8	(84.5-130.8)					
Female	68	76.0	89.5	(69.5-113.4)	Female	19	19.1	99.4	(59.8-155.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	9	13.0	69.5	(31.7-131.9)	Male	19	15.2	125.3	(75.4-195.6)
Female	0	3.7	nc	(nc-nc)	Female	21	16.3	129.0	(79.8-197.2)
Hodgkin Lym	<u>ohoma</u>				<u>Prostate</u>				
Male	2	2.9	nc	(nc-nc)	Male	273	215.2	126.8	(112.2-142.8)
Female	2	2.5	nc	(nc-nc)					
Kidney & Ren	al Pelvi	<u>s</u>			<u>Stomach</u>				
Male	21	20.6	101.9	(63.0-155.7)	Male	13	13.5	96.3	(51.2-164.7)
Female	13	13.3	98.1	(52.2-167.7)	Female	9	7.9	113.7	(51.9-215.8)
<u>Larynx</u>					<u>Testis</u>				
Male	13	8.9	145.3	(77.3-248.4)	Male	10	4.2	240.9	(115.4-443.1)
Female	4	2.4	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	17	15.4	110.7	(64.4-177.2)	Male	4	4.4	nc	(nc-nc)
Female	16	12.5	128.0	(73.1-207.9)	Female	11	13.5	81.2	(40.5-145.3)
Liver and Intra	ahepatio	Bile Duc	t <u>s</u>		Uteri Corpus and	Uterus, I	NOS		
Male	5	9.5	52.7	(17.0-123.0)	·				
Female	1	3.7	nc	(nc-nc)	Female	32	37.5	85.3	(58.3-120.4)
Lung and Bro	nchus				All Sites / Types				
Male	97	102.3	94.8	(76.9-115.6)	Male	800	691.9	115.6	(107.8-123.9)
Female	106	89.7	118.1	(96.7-142.9)	Female	673		109.4	(101.3-118.0)
				,					. ,

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Fitchburg

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003 <u>Obs</u> Ехр SIR 95% CI <u>Obs</u> <u> Exp</u> SIR 95% CI Bladder, Urinary Melanoma of Skin Male 37 40.7 90.9 (64.0-125.3)Male 13 21.1 61.6 (32.7-105.3)Female 20 16.3 123.0 (75.1-189.9)Female 11 18.1 60.7 (30.3-108.6)**Brain and Other Nervous System** Multiple Myeloma 7.6 Male 2 Male 3 nc (nc-nc) 5.8 nc (nc-nc) 9 7.2 125.4 Female 1 5.3 Female (57.2-238.1)nc (nc-nc) Non-Hodgkin Lymphoma **Breast** Male 1 1.2 nc (nc-nc) Male 18 20.6 87.5 (51.8-138.3)Female 149 153.3 97.2 (82.2-114.1) Female 22 20.7 106.2 (66.5-160.8)Cervix Uteri Oral Cavity & Pharynx Male 20 14.3 139.4 (85.1-215.3)7 7 Female 8.0 87.4 (35.0-180.1)Female 6.6 106.2 (42.6-218.8)Colon / Rectum Ovary Male 93.5 (70.8-121.2) 60.9 57 Female 66 68.0 97.1 (75.1-123.5) Female 15 16.6 90.1 (50.4-148.7)**Esophagus Pancreas** 7 Male 11 9.7 113.0 (56.3-202.2) Male 11.5 61.1 (24.5-126.0)Female 5 3.2 155.0 (50.0-361.7)Female 9 14.4 62.5 (28.5-118.7)Hodgkin Lymphoma **Prostate** Male Male 99.8 4 3.4 (nc-nc) 156 156.3 (84.8-116.8)nc Female 3 3.2 nc (nc-nc) Kidney & Renal Pelvis Stomach Male 17 105.9 (61.7-169.6) Male 9 10.3 87.5 (39.9-166.0)16.0 Female Female 9 123.1 10 11.4 87.9 (42.1-161.6)7.3 (56.2-233.7)**Larynx** <u>Testis</u> 165.0 Male 8 6.7 118.9 (51.2-234.3)Male 10 6.1 (79.0-303.4)Female 0 2.0 (nc-nc) nc **Leukemia Thyroid** 9 2 Male 12.8 70.2 (32.0-133.2)Male 4.2 nc (nc-nc) Female 8 11.9 66.9 (28.8-131.9) Female 14.0 114.7 (65.5-186.3) 16 Liver and Intrahepatic Bile Ducts Uteri Corpus and Uterus, NOS Male 9 7.4 120.9 (55.2-229.5) Female 3 3.3 nc (nc-nc) Female 24 30.7 78.2 (50.1-116.4)Lung and Bronchus All Sites / Types

• Obs = observed case count; Exp = expected case count;

76.1

74.9

Male

Female

63

55

- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

(63.6-105.9)

(55.4-95.6)

- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

82.8

73.5

Male

Female

497

484

529.4

538.5

93.9

89.9

(85.8-102.5)

(82.0-98.2)

Florida
Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

			•		iiii Standardized incident				DEO/ CI
	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>	Malanama of Chin	<u>Obs</u>	<u>Ехр</u>	<u>SIR</u>	<u>95% CI</u>
Bladder, Urinary	0	0.0		(no no)	Melanoma of Skin	0	٥٢		(ma ma)
Male	0	0.8	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	. 1	0.2	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
Brain and Other N		-	<u>1</u>		Multiple Myeloma				
Male	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					Non-Hodgkin Lymph	<u>noma</u>			
Male	0	0.0	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	5	2.8	180.7	(58.2-421.7)	Female	0	0.3	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharyr	<u>1X</u>			
					Male	1	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Colon / Rectum					<u>Ovary</u>				
Male	3	1.2	nc	(nc-nc)					
Female	0	1.0	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Esophagus					<u>Pancreas</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Hodgkin Lympho	<u>ma</u>				<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	3.6	nc	(nc-nc)
Female	1	0.0	nc	(nc-nc)					
Kidney & Renal P	<u>elvis</u>				Stomach .				
Male	1	0.4	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	1	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	1	0.0	nc	(nc-nc)					
<u>Leukemia</u>				, ,	<u>Thyroid</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Liver and Intraher	oatic B			,	Uteri Corpus and Ut	erus. NOS			, ,
Male	0	0.2	nc	(nc-nc)		,	-		
Female	0	0.1	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
Lung and Bronch			-	,	All Sites / Types			-	, - 7
Male	<u></u> 1	1.6	nc	(nc-nc)	Male	11	11.2	97.8	(48.8-175.0)
Female	2	1.2	nc	(nc-nc)	Female	14	8.9	156.5	(85.5-262.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

 $\begin{tabular}{ll} Foxborough \\ Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003 \\ \end{tabular}$

	<u>Obs</u>	<u>Ехр</u>	SIR	95% CI	with Standardized includ	Obs	<u>Ехр</u>	SIR	<u>95% CI</u>
Bladder, Urinar	У				Melanoma of Skin				
Male	12	15.9	75.4	(38.9-131.7)	Male	18	9.1	197.1	(116.7-311.5)
Female	9	5.7	157.7	(72.0-299.4)	Female	12	7.5	159.0	(82.1-277.8)
Brain and Othe	r Nervo	us Syste	<u>em</u>		Multiple Myeloma				
Male	4	3.3	nc	(nc-nc)	Male	2	2.4	nc	(nc-nc)
Female	1	2.8	nc	(nc-nc)	Female	2	1.9	nc	(nc-nc)
<u>Breast</u>					Non-Hodgkin Lym	phoma			
Male	0	0.5	nc	(nc-nc)	Male	10	8.6	116.5	(55.8-214.3)
Female	88	64.6	136.3	(109.3-168.0)	Female	8	7.6	104.6	(45.0-206.1)
Cervix Uteri					Oral Cavity & Pha	rynx			
					Male	7	6.6	105.9	(42.4-218.3)
Female	2	3.0	nc	(nc-nc)	Female	3	3.1	nc	(nc-nc)
Colon / Rectum	<u>1</u>				<u>Ovary</u>				
Male	29	24.5	118.4	(79.3-170.1)					
Female	28	23.0	121.6	(80.8-175.7)	Female	8	6.7	119.2	(51.3-234.9)
Esophagus					<u>Pancreas</u>				
Male	4	4.2	nc	(nc-nc)	Male	3	4.7	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	8	4.9	164.7	(70.9-324.4)
Hodgkin Lympl	<u>homa</u>				<u>Prostate</u>				
Male	2	1.4	nc	(nc-nc)	Male	80	68.4	117.0	(92.7-145.6)
Female	2	1.2	nc	(nc-nc)					
Kidney & Rena	<u>I Pelvis</u>				<u>Stomach</u>				
Male	9	7.1	127.0	(58.0-241.2)	Male	3	4.1	nc	(nc-nc)
Female	3	4.4	nc	(nc-nc)	Female	5	2.4	209.3	(67.5-488.5)
<u>Larynx</u>					<u>Testis</u>				
Male	1	3.0	nc	(nc-nc)	Male	5	2.5	196.2	(63.2-457.8)
Female	1	8.0	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	7	5.2	134.3	(53.8-276.7)	Male	0	1.9	nc	(nc-nc)
Female	11	4.3	258.6	(128.9-462.7)	Female	6	6.3	94.6	(34.5-205.9)
Liver and Intral	•		<u>:ts</u>		Uteri Corpus and	Uterus, N	<u>IOS</u>		
Male	2	3.3	nc	(nc-nc)					
Female	1	1.2	nc	(nc-nc)	Female	10	13.1	76.2	(36.5-140.2)
Lung and Bron					All Sites / Types				
Male	26	31.2	83.3	(54.4-122.0)	Male	242		108.8	(95.6-123.5)
Female	31	28.1	110.5	(75.0-156.8)	Female	253	208.5	121.4	(106.9-137.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Framingham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003 <u>Obs</u> **Exp** <u>SIR</u> 95% CI Obs <u>Exp</u> SIR 95% CI Bladder, Urinary Melanoma of Skin Male 63 66.5 94.7 (72.8-121.2)Male 40 36.8 108.7 (77.6-148.0)Female 28 25.3 110.5 (73.4-159.7)Female 41 31.9 128.5 (92.2-174.4)**Brain and Other Nervous System** Multiple Myeloma Male 11 13.1 83.9 (41.8-150.1)Male 16 9.7 165.1 (94.3-268.2)Female Female 8 11.9 67.0 (28.8-132.0)10 8.2 121.4 (58.1-223.2)Non-Hodgkin Lymphoma **Breast** Male 2 2.1 nc (nc-nc) Male 37 35.0 105.6 (74.3-145.6)Female 282 263.7 107.0 (94.8-120.2) Female 43 33.3 129.2 (93.5-174.0)Cervix Uteri Oral Cavity & Pharynx Male 26 25.6 101.5 (66.3-148.8)17 13.3 127.9 (74.4-204.7)Female 16 12.2 131.4 (75.0-213.3)Female Colon / Rectum Ovary Male 112 101.0 110.9 (91.3-133.4)Female 115 105.0 109.5 (90.4-131.5)Female 27 28.1 96.2 (63.4-139.9)**Esophagus Pancreas** Male 12 16.6 72.1 (37.2-126.0)Male 16 19.1 83.9 (47.9-136.3)Female 4 5.0 nc (nc-nc) Female 25 22.1 113.2 (73.2-167.1)Hodgkin Lymphoma **Prostate** Male 133.0 230 270.1 85.1 (74.5-96.9)8 6.0 (57.3-262.1) Male 2 Female 5.4 (nc-nc) nc Kidney & Renal Pelvis Stomach Male 33 27.8 118.6 (81.6-166.6) Male 20 17.1 117.2 (71.6-181.0)Female 20 18.5 108.0 (65.9-166.7)Female 13 11.2 115.9 (61.7-198.2)Larynx **Testis** 9 Male 11.7 77.3 (35.3-146.7)Male 13 11.4 113.8 (60.5-194.6)Female 3 3.3 nc (nc-nc) **Leukemia Thyroid** Male 23 21.3 108.0 (68.4-162.1)Male 10 7.7 129.5 (62.0-238.2)Female 25 132.7 (85.8-195.9) 26.4 128.8 (89.2-179.9) 18.8 Female 34 Liver and Intrahepatic Bile Ducts Uteri Corpus and Uterus, NOS Male 16 12.9 123.6 (70.6-200.8)Female 6 5.1 116.6 (42.6-253.8)Female 64 53.1 120.5 (92.8-153.8)Lung and Bronchus All Sites / Types Male 103 81.5 (66.5-98.8)Male 857 95.4 (89.1-102.0) 126.4 898.4

• Obs = observed case count; Exp = expected case count;

89.0

119.2

Female

106

- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

(72.8-107.6)

- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Female

947

887.7 106.7

(100.0-113.7)

Franklin
Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

			•		With Standardized inclu				000/ 01
Dioddon Ileinon	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>	Malanama of Chin	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
Bladder, Urinar	_	20.7	100.0	// 2 1 1FF O	Melanoma of Skin	='	10.0	00.0	(FO / 1/O 1)
Male	21	20.6	102.0	(63.1-155.9)	Male	13	13.2	98.9	(52.6-169.1)
Female	4	7.5	nc	(nc-nc)	Female	17	11.6	146.7	(85.4-235.0)
Brain and Other		-			Multiple Myeloma				
Male	6	5.1	116.8	(42.6-254.2)	Male	5	3.1	159.7	(51.5-372.7)
Female	3	4.4	nc	(nc-nc)	Female	2	2.4	nc	(nc-nc)
<u>Breast</u>					Non-Hodgkin Lym	<u>iphoma</u>			
Male	0	0.7	nc	(nc-nc)	Male	9	12.2	73.9	(33.7-140.3)
Female	105	92.6	113.4	(92.8-137.3)	Female	10	10.6	94.3	(45.1-173.4)
Cervix Uteri					Oral Cavity & Pha	<u>rynx</u>			
					Male	9	9.2	98.0	(44.7-186.0)
Female	4	4.9	nc	(nc-nc)	Female	4	4.4	nc	(nc-nc)
Colon / Rectum	<u> </u>				<u>Ovary</u>				
Male	37	32.2	115.0	(81.0-158.5)					
Female	31	30.5	101.6	(69.0-144.2)	Female	12	9.5	125.8	(64.9-219.7)
Esophagus					<u>Pancreas</u>				
Male	5	5.5	91.4	(29.4-213.2)	Male	5	6.1	82.2	(26.5-191.7)
Female	3	1.5	nc	(nc-nc)	Female	6	6.3	94.6	(34.5-205.9)
Hodgkin Lymph	noma				<u>Prostate</u>				
Male	1	2.4	nc	(nc-nc)	Male	99	87.4	113.3	(92.0-137.9)
Female	3	2.1	nc	(nc-nc)					
Kidney & Renal	Pelvis				Stomach				
Male	9	9.7	92.4	(42.2-175.5)	Male	5	5.4	92.3	(29.7-215.4)
Female	3	6.1	nc	(nc-nc)	Female	2	3.2	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	3	3.9	nc	(nc-nc)	Male	6	4.8	124.8	(45.6-271.6)
Female	1	1.1	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	5	7.5	66.4	(21.4-154.9)	Male	3	3.1	nc	(nc-nc)
Female	8	6.3	126.4	(54.4-249.0)	Female	8	10.8	73.9	(31.8-145.5)
Liver and Intrah	nepatic E			,	Uteri Corpus and	Uterus, N			,
Male	0	4.6	nc nc	(nc-nc)	•	•			
Female	2	1.5	nc	(nc-nc)	Female	15	18.0	83.4	(46.7-137.6)
Lung and Brone	chus			. ,	All Sites / Types				. ,
Male	41	40.3	101.8	(73.0-138.1)	Male	298	297.0	100.4	(89.3-112.4)
Female	28	36.6	76.4	(50.8-110.4)	Female	293	292.4		(89.1-112.4)
				(· · - · · /					,

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;